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A dosimetric study of the beta-minus emitter Praseodymium-142 (142Pr) was performed 
and two main innovative applications of this source in brachytherapy are proposed: microsphere 
brachytherapy and eye plaque brachytherapy. 142Pr (96.3% beta and 3.7% gamma) has recently 
gained increased attention among beta sources for therapy. Its inherent physical and dosimetric 
characteristics may be suitable for several brachytherapy applications. This relatively short half-
life (19.12 h) allows this source to deliver high dose rates to the target. Penetration of the beta 
component of 142Pr radiation in tissue is limited to a few millimeters, therefore limiting dose 
deposition to the treated site. The large neutron activation cross-section of the parent isotope 
(11.40 barn including that of a meta-stable state) allows the activation of this nuclide in a low 
neutron fluence reactor, making its production easily available for both research and therapy 
purposes. From simulations and measurement of the doses, exposure rates due to the 3.7% 
gamma component showed to be clinically small for the patients’ healthy organs and tissues as 
well as to medical staff and general public. Furthermore, it was studied whether its gamma 
	  component could be effective in performing pre-treatment quality assurance (QA) and dosimetry, 
as well as post-treatment biodistribution imaging and dose distributions of permanently 
implanted 142Pr brachytherapy sources. Two main novel applications of 142Pr beta emitters are 
studied in this work: (i) 142Pr glass microspheres, as a possible choice of radionuclide for 
microsphere brachytherapy of nonresectable hepatocellular carcinoma (HCC) and metastasis of 
the liver, and (ii) 142Pr glass rods for brachytherapy of ocular squamous cell carcinoma (OSCC), 
based on a novel design for eye brachytherapy – also developed in this work. In order to simulate 
the dosimetric characteristics of 142Pr, MCNPX2.6 Monte Carlo code and BRAIN-DOSE Dose 
Point Kernel code were used to determine the dose distributions of 142Pr for different source 
distributions. Dosimetric properties of the currently used nuclide in microsphere brachytherapy, 
Yttrium-90 (90Y), was also studied and compared to 142Pr. A more realistic biodistribution model 
of microspheres within a single HCCs blood vessel was studied. In addition, the biological 
effective dose (BED) for different tumor doubling times (DT) for HCC was determined using the 
linear quadratic (LQ) model for both nuclides. Dose distributions for 142Pr, 90Y and Rhenium-188 
were simulated within the eyeball and compared for application in eye brachytherapy. 
Measurements of dose distribution using GAFCHROMIC® EBT2 film were performed with 
142Pr glass microspheres and 142Pr glass rods. Monte Carlo simulation validation with 
experimental measurements in phantom of the dose distribution due to 142Pr glass microspheres 
and 142Pr glass rods were performed. 142Pr showed to be a possible choice of radionuclide for 
HCC microsphere brachytherapy and OSCC brachytherapy, delivering a high biological 
effective dose, and opening possibilities for post treatment imaging and biodistribution 
assessment.  
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CHAPTER 1: INTRODUCTION 
1.1 Importance of Brachytherapy in the current clinical practice 
Brachytherapy, from the Greek word brachys, meaning “short-distance", is a form of 
internal radiotherapy, in which a short-range radiation source is placed inside or near the tumor. 
Brachytherapy can be used to treat several body sites and it has been used as an effective 
treatment for prostate, breast, skin, and cervical cancer. This technique allows the localization of 
high doses of radiation to the tumor, while sparing surrounding healthy tissues. Because it is 
highly targeted, brachytherapy presents lower risks of side effects due to radiation and is usually 
well tolerated. Brachytherapy can be used in combination with other techniques, such as external 
beam radiation therapy (EBRT) and chemotherapy. 
Shortly after the discovery of radioactivity by Henri Becquerel in 1896, radioactive 
sources were used in a variety of medical treatments. The first reported case of radiation being 
used in the treatment of cancer was in 1899. Marie and Pierre Currie were the first to suggest that 
radioactive sources could be implanted in or near tumors.  This was the beginning of 
brachytherapy, at the time known as curietherapy. The Curie institute in Paris pioneered the 
improvement and development of the technique in the earlier twentieth century, developing 
successful treatment schedules for gynecologic malignancies. 
Radium sources were the most common type of internal source used during the 1930s. 
Gold seeds filled with radon were developed in 1942 and used until 1958. After the World War 
II, Cobalt needles were used for a short period of time, but were ultimately replaced by tantalum 
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and gold. Iridium sources were first used in 1958, and these continue to be the most commonly 
used radioactive sources for brachytherapy. 
Due to the unnecessary radiation exposure to operators, the use of brachytherapy declined 
in the middle twentieth century in Europe and in the United States. It was only with the 
improvement of remote after-loading and computerized dose calculation techniques, in the 1950s 
and 1960s, that brachytherapy regained interest in the medical community. After-loading 
techniques allow the therapist to deliver the seeds remotely, therefore decreasing the risk of 
unnecessary radiation exposure. This technique uses hollow catheters or guide tubes inserted in 
the target volume, which are then loaded with radioactive sources. Improvements in the dose 
calculations prior to interstitial brachytherapy treatment made it possible to plan a homogeneous 
tumor dose distribution, avoiding hot spots in the tumor and surrounding healthy tissues. 
A large variety of clinical instrumentation is currently available for implementing 
numerous types of brachytherapy procedures (Nath et al., 1997). The types of brachytherapy 
techniques can be classified according to (i) the place where the seeds are implanted, (ii) the dose 
rate that the radiation is delivered and (iii) the duration of the dose delivery.  
Radioactive seeds can be placed within the target tissue or interstitially, e.g. in the 
prostate or in the breast, or it can be placed in contact or next to the treated area, such as a body 
cavity, e.g. cervix, uterus or vagina, or a body surface, e.g. skin. Radiation sources can also be 
placed in blood vessels (intravascular brachytherapy), e.g. coronary and liver blood vessels. 
Intraluminal brachytherapy is also used for treating tumors that obstruct the opening of hollow 
organs, such as pulmonary bronchus, biliary duct, and esophagus. 
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The dose rate (Gray per hour) at which the radiation is delivered can be classified in two 
general categories: low dose rate (LDR) and high dose rate (HDR) brachytherapy. Dose rates of 
LDR brachytherapy go up to 2 Gy/h, from radium, cesium, cobalt, or iridium sources and it is 
usually used to treat the oral cavity, oropharynx, sarcomas, cervix and prostate cancers. In the 
past few decades, HDR has been developed as an alternative method for brachytherapy. In HDR 
brachytherapy, dose rates are greater than 12 Gy/h, (ICRU Report 38) a rate commonly used in 
linear accelerators for external beam therapy (Nath et al., 2007), and is used for treating lungs, 
breast, cervix, and prostate cancers. In most cases, HDR brachytherapy is performed in an 
outpatient basis. The radiation source can either be implanted permanently or temporarily placed 
in or near the treatment site. Temporary brachytherapy involves placement of radiation sources 
for a certain period of time before being withdrawn. In permanent brachytherapy, also known as 
seed implantation, small radioactive seeds are implanted permanently in the tumor or treatment 
site. 
Many radionuclides have been studied for use in brachytherapy.  These sources have a 
wide range of half-lives and energies (Häfeli, 2001). Several brachytherapy sources are currently 
available for use, and these sources vary in shape, size, and radionuclide used. Each source type 
may have a different application or medical purpose, depending on their radiation energy, 
dosimetric characteristics and physical properties. Radiation sources used for medical 
applications may emit alpha, beta or gamma radiation. In the current work, the beta-minus 
emitter 142Pr was studied. Table 1.1 lists several beta-emitters and their radiological properties, 
such as half-life, average and maximum beta energy, gamma emissions with their percentage 
yield, etc.   
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Table 1.1 Property of beta-emitter radionuclides used in radiation therapy 
Radioisotope Half-
Life 
Average/Max  
Beta Energy 
(keV)† 
Max. range 
in tissue 
(mm)* 
Gamma Production 
3H 12.3 y 5.7 / 18.0 5.48 × 10-3 none 6Li(n,α)3H 
14C 5730 y 49.5 / 156.0 0.287 none 14N(n,p)14C 
32P 14.3 d 694.9 / 1710.2 7.90 none 
32S(n,p)32P or 
31P(n,γ)32P 
90Y 64.1 h 933.6 / 2280.0 10.9 none 90Sr/90Y generator 
131I 8.0 d 181.7 / 806.9 2.4 364.5 keV (82.5%) 131Te (β-) 131I 
142Pr 19.12 h 809.0 / 2162.0 10.3 1580 keV (3.7%) 141Pr(n, γ )142Pr 
153Sm 46.5 h 224.2 / 808.2 3.0 103.2 keV (29.8%) 152Sm(n,γ)153Sm 
165Dy 2.3 h 440.2 / 1286.7 6.4 94.7 keV (3.6%) 164Dy(n,γ)165Dy 
166Ho 26.8 h 665.1 / 1853.9 10.2 80.6 keV (6.7%) 165Ho(n,γ)166Ho 
169Er 9.4 d 99.6 / 350.9 1.0 < 0.2% 168Er(n,γ)169Er 
177Lu 6.7 d 133.3 / 497.8 1.7 113.0 keV (6.4%)  
208.4 keV (11%) 
176Lu(n,γ)177Lu 
186Re 89.2 h 346.7 / 1069.5 5.0 137.2 keV (9.42%) 185Re(n,γ)186Re 
188Re 17.0 h 764.3 / 2120.4 10.0 155.0 keV (15.1%) 
188W/188Re 
generator 
198Au 2.7 d 311.5 / 960.7 4.4 411.8 keV (95.5%) 197Au(n,γ)198Au 
†NuDat database (Kinsey, 1998) 
*Calculated using empirical formula (Katz and Penfold, 1952)  
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In order to deliver significant radiation doses to the treatment area, applicator 
modifications, insertion techniques, dose specification, and new radionuclides have been 
developed for LDR and HDR brachytherapy. In the following sections, the background 
information on microsphere brachytherapy and eye plaque brachytherapy will be discussed and 
the rational for the needed improvement of these techniques will be explained. 
1.2 Hepatocellular Carcinoma (HCC) and 142Pr Microsphere Brachytherapy 
The liver is a vital organ that has several functions, such as breaking down and storing 
nutrients from the intestine, generating clotting factors needed to stop bleeding from injures, 
producing bile essential for the absorption of nutrients in the intestine, breaking down toxic 
waste and filtering the blood, among other functions. The liver is the largest internal organ of the 
human body. It is divided onto right and left lobe. It receives blood supply from two different 
sources: the portal vein (blood rich in nutrients from the intestine) and the hepatic artery (blood 
rich in oxygen). 
Both malignant and benign tumors can develop in the liver. The most common type of 
malignant liver cancer in adults is hepatocellular carcinoma (HCC) (primary) and metastasized 
colon cancer (secondary). About 80% of the primary liver cancers are HCC. Primary HCC can 
be classified into two main groups: a primary single tumor, that grows then spreads to other liver 
sites, or multiple primary tumors throughout the liver (usually as a consequence of other ongoing 
liver cells damage or cirrhosis). The latter is the most common type in the United States and the 
frequency of this type of HCC has been increasing throughout western countries (Hennequin et 
al., 2011). In 2013 it is estimated that 30,640 new cases of primary liver cancer will be diagnosed 
in the United States. Of these cases, an estimated 21,670 will be fatal. Liver cancer is more 
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common on the continents of Africa (especially in sub-Saharan countries) and Asia 
(predominantly in the eastern countries) (ACS Liver Cancer, 2012). 
Tumors can be either resectable, i.e. removable through surgery, or nonresectable. 
Determining whether a tumor is resectable depends on the location, size, patient overall health 
conditions, as well as a variety of other factors. There has to be sufficient hepatic parenchyma 
left after surgery for the proper functioning of the organ, meaning that the tumor have to be small 
enough and have a well-defined border. Although surgical removal of liver tumors may offer the 
best cure rates, more than 75% of primary liver tumors and 90% of secondary liver tumors are 
nonresectable.  
There are different methods for treating liver tumors that are difficult to reach or 
nonresectable. Currently available methods are: stereotactic body radiosurgery, cyber knife 
radiosurgery (Bianciotto et al. 2010), microsphere radioembolization, transarterial 
chemoembolization, radiofrequency ablation, etc. The choice of the treatment method depends 
on the stage of the disease, the patient treatment preferences, the available methods in a given 
cancer center, as well as the treatment cost.  
One of the challenges of treating hepatocellular carcinoma with radiation is the fact that 
hepatic tumor are radioresistant, while liver parenchyma cells are radiosensitive. This limits the 
amount of dose that can be delivered by conventional external beam radiotherapy, since the 
normal hepatic parenchyma cannot tolerate high doses. The maximum external dose tolerated by 
the whole liver is 35 Gy fractionated in 1.8 Gy per day (Dezarn et al., 2011). New methods 
focusing on a more targeted approach began to emerge in response to the challenge presented by 
the radiosensitivity of hepatic parenchyma. Microsphere brachytherapy is an example of 
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treatment capable of delivering high doses to specific parts of the liver, allowing the treatment of 
tumor sites while sparing normal tissue.  
Microsphere brachytherapy has gained an increased importance among cancer treatment 
modalities and research topics in radiotherapy (Salem and Thurston, 2006; Council Steering 
Committee, 2008; Kennedy et al., 2007; Dezarn et al., 2011). Radioactive microspheres have 
sizes ranging from 10 to 30 µm, meaning they are larger than capillaries and are easily trapped in 
the capillary beds. These spheres remain permanently implanted and deliver radiation dose 
locally (Häfeli, 2001). It is a selective internal radiation therapy (SIRT), in which the target 
organ or tumor site receives a high dose of radiation, while the surrounding healthy tissue 
receives a very low dose when compared to other treatment modalities, e.g. external beam 
radiation therapy (EBRT). Typical effective treatment range in tissue is up to several millimeters 
for beta-emitters. At the present stage, the technique has been used for unresectable liver tumors 
cases in which standard treatments, such as chemotherapy and radiotherapy, have failed to treat 
the malignancy. Microsphere brachytherapy is a palliative, not curative, treatment. However, 
patients have benefited from this treatment through life-extension and improvements in quality 
of life. 
Microsphere brachytherapy was originally used to treat patients with rheumatoid arthritis, 
ovarian and pancreatic cancer, and primary and metastatic hepatic tumors. This technique is 
particularly effective in treating arthritis, delivering a targeted dose to the membrane for 
treatment or ablation of synovium and reducing joint effusion. In the treatment of ovarian cancer, 
the microspheres are introduced through the abdominal cavity and deliver radiation to the cancer 
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cells. Microsphere brachytherapy has also been effective in controlling growth in benign cystic 
brain lesions, craniopharyngioma, as well as pancreatic and hepatic tumors. 
One of the first beta-emitters used in microsphere brachytherapy for the treatment of lung 
tumors was 198Au (size 30-50 µm). However, 198Au also emits high-energy γ-rays (0.985% 
gamma yield of 1087.8 keV photons and 98.99% gamma yield of 418 keV photons) (Spillane et 
al., 2007). The high yield of gamma emissions (greater than 99%) that follows the beta decay led 
to high radiation exposure to the other organs of the patient, as well as to the caregivers. In an 
attempt to overcome this issue, pure beta-emitters, such as Phosphorous-32 (32P) and Yttrium-90 
(90Y) became the predominant radioisotopes for many therapeutic applications during the past 
decade. Recently, however, it has been shown that a few percent of low-energy γ-radiation can 
actually be useful for imaging, either during or after the delivery of the microspheres (Höesler et 
al., 2004). With the help of gamma cameras, the surgeons are able to direct the radioactive 
microspheres and adjust the necessary amounts of radioactivity during the process of 
microsphere embolization (Häfeli, 2001). 
It has been shown that not only is the total dose delivered important for predicting 
treatment outcome in radiotherapy, dose rate is also an important parameter (Hall and Brenner, 
1992). Short-lived radioisotopes may be used to optimize radiobiologic aspects of therapy. Short-
lived radioisotopes such as Dysprosium-165 (165Dy) and Rhenium-188 (188Re) deliver the total 
dose in a much shorter period of time, allowing less time for tumor cells to recover and 
repopulate. Although there is still a need for more research in this area, beta-emitting lanthanides 
are seen as promising for microsphere brachytherapy. 
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Several beta emitters, such as 90Y, Samarium-153 (153Sm), 188Re, 32P, Holmium (166Ho) 
and 142Pr have been studied and their use in brachytherapy and microsphere brachytherapy has 
been increasing (Kennedy et al., 2006; Sadeghi et al., 2010; Fischer and Kampen, 2012; Conzone 
et al., 1998; Oehme and Kotzerke, 2009; Coursey and Nath, 2000; Turner et al., 1994; Squair et 
al., 2012; Lee and Reece, 2005; Jung and Reece, 2008). The most popular radioisotope currently 
used in microsphere brachytherapy is 90Y. It is found in the form of glass or resin microsphere, 
under the brand names of SIR-Sphere® (Sirtex Medical Limited, North Sydney, NSW, Australia) 
and TheraSphere® (Nordion Inc., Ottawa, ON, Canada).  
Production of 90Y is considered challenging and costly (Hamoudeh et al., 2008). 
Availability and costs are therefore limiting factors for research improvements and widespread 
clinical use of the technique. Another issue related to the nuclide is the difficulty of appropriate 
verification of the microspheres activity for quality assurance (Dezarn et al., 2011). The activity 
of 90Y microspheres is usually calculated based on the time elapsed since the sample was 
produced, the half-life, and initial activity provided by the vendor. Direct verification of the total 
activity at the treatment site has been challenging because 90Y is mostly a beta emitter (it also 
undergoes internal pair production determined to be 31.87 ± 0.47 × 10-6) (Gates et al., 2011). 
This presents an issue if only part of the total activity of the microspheres will be used for 
treatment. The gamma component of 142Pr would allow a direct verification of the remaining 
sample activity and therefore a better estimation of the dose delivered to the patient.  
Another important factor to consider is the biological effective dose (BED) received by 
the hepatic parenchyma and HCC, which varies greatly with the radionuclides used. This 
property is related to the dose delivery time of the radionuclide, as well as the rate of growth and 
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repopulation, repair rate, and other biological factors of the tumor or tissue considered (Hall, 
2000). Dose delivery time is mainly related to the radionuclide half-life. Optimization of half-life 
to obtain the maximum efficiency in delivering the total dose has been studied previously. 
Armpilia et al. (2003) considered biological factors and tumor growth rates applied in the 
quadratic model for the assessment of BED values. Results obtained by Armpilia et al. suggest 
that radionuclides with shorter half-life may produce better clinical results. However, the shorter 
half-life may also give a higher dose to normal tissues. Therefore special care is necessary not to 
cause failure of selective delivery, i.e lung shunting (Oehme and Kotzerke, 2009; Cremonesi et 
al., 2008; Dale, 1996). Lung shunting is characterized by the intake of microspheres by the lungs 
and it may be more prominent in some patients than others. 
In the present work 142Pr was studied as a possible choice of radionuclide for microsphere 
brachytherapy. The contribution to the total dose and dose distribution due to the beta and 
gamma emission of 142Pr was studied and compared with the dose distribution due to 90Y (a pure 
beta emitter). Tumors and blood vessels were modeled and simulated using MCNPX2.6 (Monte 
Carlo Team, 2008) (Monte Carlo Team, 2008). Dose distributions due to both nuclides were 
calculated and compared. This study aims to evaluate the feasibility of the radionuclide 142Pr as a 
possible nuclide for microsphere brachytherapy. This work includes modeling of single blood 
vessel and simulation of the dose distribution, direct measurements of dose delivered by 
microspheres, and Monte Carlo validation with experimental data. 
1.3 Ocular Squamous Cell Carcinoma (OSCC) and 142Pr Eye Brachytherapy 
According to the American Cancer Society (ACS Eye Cancer, 2013), an estimated 2,610 
cases of cancer in the eye and eye orbit will be diagnosed in 2013 (1,310 males, 1,300 females), 
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with an estimated 270 deaths (120 males, 150 females). Secondary eye cancer, metastasized from 
other organs, is more common than primary eye cancers. Eye cancer can occur at any age, but 
most commonly occurs in patients over age 50. The two main types of eye cancer are 
retinoblastoma and melanoma. Retinoblastomas are more common among children under age 
five. Malignant melanomas present on average at age 60 to 65. These tumors may cause pain and 
impair vision. These tumor types may metastasize to the optic nerve, brain, and eye orbit. Early 
detection and treatment is important to prevent sight losses and spread of the disease. 
There are currently several modalities available to treat eye tumors. The most common 
techniques are: eye plaque brachytherapy (Chiu-Tsao et al., 2012), external beam radiotherapy 
(photon and proton), photocoagulation and photodynamic therapy, chemotherapy, cryotherapy 
(freezing affected area), and enucleation (removal of the eyeball). Resection of the tumors may 
cause sight loss and may not prevent disease recurrence in the eye or eye orbit.  
Currently available low dose rate (LDR) brachytherapy techniques have shown low 
recurrence rates, but may be followed by severe side effects, such as permanent loss of the 
eyelashes and progressive visual acuity deterioration, among others (Nag et al., 2003). 
Conventional eye brachytherapy is based on standard spherical shaped plaques (Supe et al., 
1975). These plaques present some geometrical limitations. Eye plaques were designed to deliver 
uniform fields to the eyeball, restricting the options for planning a tumor specific dose 
distribution. Advances have been made in other branches of brachytherapy that allow the 
delivery of a conformal dose to the tumor, e.g. after load seed implantation for prostate cancer 
and gynecologic interstitial implant (Thibault and Vigneault, 2011), and microsphere 
brachytherapy for liver cancer treatment. For episcleral eye brachytherapy however, the current 
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eye plaque is limited to a circular concave shape to fit the eyeball. These plaques do not take into 
account the specific patient eye anatomy or the specific tumor shape. 
In order to overcome the limitations of the present method, the proposed device was 
designed to deliver a more conformal dose throughout the tumor, taking into account patient 
specific tumor shape and eye anatomy, as well as providing a faster dose delivery. High dose rate 
(HDR) brachytherapy using beta emitters can treat superficial tumors in few minutes, as opposed 
to LDR, which typically takes several days. Penetration of this type of radiation in tissue is small 
and healthy structures in the treated eye can be spared from unwanted radiation. 
A conformal eye applicator, or conformal eye brachytherapy (CEBT) device, was 
developed in this work. It was intended to improve the current state and concept of eye plaque 
brachytherapy, by proposing a more conformal and patient specific dose profile. The novel 
device has to fulfill three primary treatment requirements: (i) to improve the spatial precision of 
the dose delivered to the target volume, (ii) to increase the tumor control probability while 
decreasing tissue complications by sparing the surrounding healthy tissue and increasing the total 
dose delivered to the target and (iii) to optimize the treatment effectiveness by increasing the 
dose rate and decreasing the treatment time. 
Current methods used in eye plaque brachytherapy do not allow planning for a tumor 
specific dose distribution. Eye plaques consist of a small pre-molded concave metal plaque, 
which is used as a base for inserting radioactive seeds. The plaque is then sewn on to the sclera, 
where it stays for several days. In this technique, a homogeneous dose distribution is delivered 
throughout the eye surface, irradiating a significant amount of healthy tissue with the 
prescription dose. As a consequence, the patient may develop severe side effects, including loss 
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of sight. Traditional eye plaque design is suitable for round, homogeneous tumors. However, 
most of the tumors present nonhomogeneous shapes with variable sizes.  
The conformal eye brachytherapy (CEBT) device allows the physician to plan a treatment 
based on patient specific anatomy and tumor shape and size, allowing for a more conformal dose 
to the tumor volume. This technique was inspired by the concept of intensity modulated radiation 
therapy (IMRT), in which photon fluence can be controlled to deliver a targeted dose to the 
tumor. IMRT uses a segmental approach to achieve a final desired dose to the target. To achieve 
the planned dose to the target, the multi-leaf collimator shapes the beam into different patterns. 
The segments can be overlapped in order to form a three-dimensional dose distribution within 
the patient. However, for the CEBT the dose will be limited to the surface and shallow depths, 
since its proposition uses a beta-emitter and most of the dose will be limited to within a few 
millimeters of the eye surface. In the proposed device, the radioactive sources are independently 
controlled by a computed system. They are free to move and can be positioned in different 
arrangements, allowing several fields to overlap to meet the desired dose distribution to the 
target. 
In this work, the CEBT device design is described. The viability of 142Pr as a radionuclide 
for treating OSCC is studied using MCNPX2.6 Monte Carlo Simulation. A priori this device is 
proposed specifically for eye tumors. However, based on its geometric characteristics and 
physical properties, it may be suitable for treating other types of superficial tumors. Due to the 
highly localized doses delivered by this device, its use could be extended to the treatment of 
body sites such as melanomas and squamous cell carcinomas, or cancer located in the eyelid, ear, 
nose, lip, fingers, toes, tongue and sexual organs (Sedda et al., 2011). The device was designed 
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to be reusable after proper sterilization and radionuclide reactivation. Total dose can be delivered 
within a few minutes because of the high dose rate provided by short-lived nuclides such as 
142Pr. No surgical procedure is necessary, so treatment can be performed on an outpatient basis. 
The procedure does not require source implantation, so there is no need for patient isolation from 
family and caregivers after treatment. In summary, the three main aims of this proposal are: (i) to 
design a conformal eye brachytherapy (CEBT) device for a tumor specific treatment, (ii) to 
perform simulations and dose distribution measurements within the modeled eyeball for the 
nuclide proposed, and (iii) to simulate and compare different nuclides and their dose distribution 
for the eye applicator. Future work includes: (i) to develop a planning system to customize the 
radiation coverage for a target volume, and (ii) to develop a quality assurance method for 
verification of the device and treatment plan. 
1.4 MCNPX2.6 Monte Carlo Radiation Transport Code 
MCNPX, Monte Carlo N-Particle eXtended, is a general-purpose Monte Carlo radiation 
transport code for modeling the interaction of radiation with matter. MCNPX extends the 
capabilities of previous versions of MCNP code by allowing the tracking of more particles, 
wider energy ranges, and by allowing a wider variety of applications to be simulated. The code 
was developed and is maintained by the Los Alamos National Laboratory (LANL) and uses 
Monte Carlo (MC) method for simulation of the particle tracks. MCNPX2.6 (Monte Carlo Team, 
2008) is an extension of MCNP5. Simulations were benchmarked with accepted results from the 
literature for known dose distributions (Berger, 1971). MCNPX2.6 has a broad available nuclear 
data library, in regard to cross-sections for different particles and energy. It has numerous 
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applications in radiation measurements, such as high-energy dosimetry and neutron detection and 
in Medical physics, especially proton and neutron therapy. 
Convolution techniques are often used for photon and electron dose calculation. These 
methods are fast and have a good agreement with Monte Carlo simulations for simple geometries 
(Mainegra-Hing et al., 2005). Convolution techniques calculate the total dose by convolving the 
total energy released per unit mass with a dose point kernel (DPK), which is the radial 
distribution of dose around an isotropic point source in an inﬁnite water medium. DPK is used to 
calculate dose delivered by electrons and has no angular information. 
Dose rates due to 142Pr and 90Y point sources were calculated using the BRAIN-DOSE 
DPK code (Dauffy, 1998). The BRAIN-DOSE code is based on SADDE (Reece et al., 1989) and 
VARSKIN (Traub et al., 1987) codes. BRAIN-DOSE code uses the dose point kernel (DPK) 
method to integrate the Berger point kernels over the source volume using the scaled point 
kernels tabulated by Berger (1971): 
𝐵 𝜌,𝐸 = 14𝜋𝛿𝜌! 𝐸𝑁(𝐸)𝑋!" 𝐹 𝜌𝑋!" ,𝐸 𝑑𝐸!!"#!  Eq. 1.1 
Where ρ is the distance between source point and dose point (cm); δ is the density of the 
irradiated medium (value used was 1.00 g/cm3 for water); N(E) is the probability that a β- particle 
is emitted with Energy E; X90 is the radius (cm) of the sphere within which 90% of the beta 
energy is deposited from a point source in an infinite medium; and F is a function of ρ and X90 
and represents the dimensionless scaled absorbed dose distribution. 
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Dose rates for point sources using both nuclides were calculated using the MCNPX2.6 
Monte Carlo code. It has been shown that MCNPX2.6 can been used successfully for the 
calculation of dose distributions for electrons when using ITS-style (DBCN 18 card=1), also 
called the “nearest group boundary” treatment, and it has been shown to be in agreement with 
other versions of MCNP code (Nedaie et al., 2006; Schaart et al., 2002). It can be used for 
calculating several particle types, such as neutron, photon, electron, or coupled 
neutron/photon/electron transport. Secondary radiations such as positrons, K-edge characteristic 
x-rays, and bremsstrahlung are included in the default modeling of MCNPX2.6.  
The continuous-slowing-down model is used for the electron transport simulation. This 
model takes into account several factors, including electron energy, total path length and total 
stopping power of the electron, the electron collisional stopping power due to collisions between 
particle and atoms, the electron radioactive stopping power due to energy loss during interactions 
with the Coulomb force field of the atoms or Bremsstrahlung, statistical variations in the amount 
of energy lost in each collision, or energy straggling, and multiple scattering distributions.  
The geometry of the sources was modeled and a series of three-dimensional mesh tallies 
(finite volumes used as detectors by MCNPX2.6 for the 3D mapping of the energy deposited in 
the medium) were positioned along the dose tally points. The energy cutoff used both electron 
and photon was 0.001 MeV, which is the default value used by MCNPX2.6 for these particles. 
The number of source electron histories (NPS) was chosen so that there was less than 1.5 % 
statistical error for the points of interest, such as the points close to the source. To obtain less 
than 1.5 % statistical error at least 2.0 × 107 NPS were required per simulation. The “ITS-style” 
energy-indexing algorithm (DBCN 18 card=1) was used. The default ESTEP parameter (number 
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of sub-steps per energy step depends on the material in which the electrons are traveling and 
ranges from 2 for Z = 3 to 15 for Z > 90) was defined in the material card (Reynaert et al., 2002). 
1.5 Biological Effective Dose (BED) and the Linear Quadratic (LQ) Model 
It is useful to have a quantitative method of comparing treatment effectiveness. The 
Linear Quadratic (LQ) model is the most widely used method for comparing effective dose in 
radiotherapy. In this model, the biological effect is not only a function of dose but also the dose 
rate at which the radiation is delivered. The tissue radiosensitivity to a given radiation type is 
modeled by the parameters α and 𝛽. According to the LQ model (Lea and Catcheside, 1942; Lea, 
1947; Fowler, 1989; Antipas et al., 2011; Armpilia et al., 2013), the percent survival of cells as a 
function of dose is given by: 
𝑆 = 𝑒!!"!!!! Eq. 1.2 
The Biological Effective Dose (BED) values were calculated for both 142Pr and 90Y. 
Considering the relative biological effectiveness (RBE), the BED is calculated as the prescribed 
total dose (TD) times the relative effectiveness (RE) factor minus biological equivalent of the 
tumor repopulation (BRF): 
𝐵𝐸𝐷 = 𝑇𝐷 𝑅𝐸 − 𝐵𝑅𝐹 Eq. 1.3 
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Each term of this equation will be defined in the following equations. The total dose is expressed 
as: 
𝑇𝐷 = 𝑅!𝜆 [1− 𝑒(!!!!"")] Eq. 1.4 
where, R0 is the initial dose rate, λ is the radionuclide decay constant (h-1), and Teff is the effective 
treatment time (h), given by: 
𝑇!"" = − 1𝜆 𝑙𝑛 𝐾𝑅𝐵𝐸!"#𝑅!  Eq. 1.5 
with K being the tumor repopulation factor (Gy/h), the biological dose required to offset each 
day’s worth of tumor repopulation, given by: 
𝐾 = 𝑙𝑛(2) (𝛼𝐷𝑇) Eq. 1.6 
and RBEmax is the maximum RBE defined as the ratio of linear sensitivity coefficient (α) for high 
LET test radiation to that for a reference low LET radiation. RBEmax used in these calculations 
was 1.0. The relative effectiveness (RE) can be expressed as: 
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𝑅𝐸 = 𝑅𝐵𝐸!"# + 2𝑅!𝜆𝜇!"# − 𝜆 𝛼/𝛽!"# 𝐴(𝐵 − 𝐶) Eq. 1.7  
where A, B, and C are defined as: 
𝐴 = 11− 𝑒𝑥𝑝 −𝜆𝑇!"" ,                   Eq. 1.8 
𝐵 = 1− 𝑒𝑥𝑝 −2𝜆𝑇!""2𝜆 ,                 Eq. 1.9 
𝐶 =   1− 𝑒𝑥𝑝[−𝑇!""(𝜇!"# + 𝜆)]𝜇!"# + 𝜆  Eq. 1.10 
with µtum being the sublethal damage repair constant (h-1), (α/β)tum the inverse fractionation factor 
of the tumor (Gy), α the linear radiosensitivity coefficient (Gy-1), and DT the average clonogen 
doubling time (h).  
1.6 Beta Emitter Praseodymium-142: Radionuclide Properties 
The production of several radionuclides, including 32P, 90Y and 142Pr, is performed by 
means of neutron activation (NA) in neutron reactors. This method consists of bombarding the 
parent atoms with a flux of neutrons. The activity reached through NA is proportional to the 
number of atoms in the sample, the neutron flux in the reactor, the neutron energy, the parent 
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neutron absorption cross section and the amount of time that the parent is exposed to the neutron 
flux. Details of neutron activation parameters are discussed in Section 1.8 Radionuclide 
Production. Radionuclides with higher activation cross-section reach a higher saturation activity 
than ones with lower activation cross-section. Therefore, smaller cross sections require higher 
neutron fluence for activation (the most commonly used unit for cross section is barn, where 
1 barn = 10-24 cm2. For instance, 32P has a smaller thermal neutron absorption cross-section of the 
parent (0.18 barn) and lower beta maximum energy (Emax 1.709 MeV) when compared to 90Y 
(cross section of the parent σ = 1.28 barn and Emax =2.284 MeV). On the other hand, 142Pr 
presents a higher neutron absorption cross-section of the parent (11.40 barn) and relatively high 
maximum beta energy (Emax 2.162 MeV). The higher neutron absorption cross-section of the 
parent for 142Pr when compared to 90Y (1.28 barn) allows for faster production and allows for the 
possibility of activation in low neutron fluence reactors. Some authors also suggest the 
possibility of activation of 142Pr using cyclotrons (Sadeghi et al., 2011).  
1.7 Electron maximum range 
Maximum range in tissue for several beta emitter nuclides used in therapy are shown in 
Table 1.1.The maximum range of electron emitted by these nuclides can be calculated using the 
empirical formula (Katz and Penfold, 1952): 
𝑅!"# 𝑔 𝑐𝑚! = 0.412  𝐸!!.!"#!!.!"#$ ln!!           𝑓𝑜𝑟      0.01 ≤ 𝐸! ≤ 2.5𝑀𝑒𝑉 Eq. 1.11 
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where Eβ is the maximum beta energy in MeV. Range in Eq. 1.11 is expressed as a density 
thickness (g/cm2) and it is material independent. The range, expressed as a distance, can be 
calculated for different materials by dividing Rmax by the material density. For instance, the 
maximum electron range for 142Pr in water is 10.3 mm, which is comparable to the maximum 
range for 90Y (10.9 mm), and for 32P this value is 7.90 mm. 
1.8 Decay modes of Praseodymium-142 
142Pr has a half-life of 19.12 hours and undergoes two decay modes: beta-minus emission 
(β-) and electron capture (EC). In the beta-minus decay (99.98%), a neutron in the 141Pr nucleus 
is transformed into a proton and electron: 
𝑛 → 𝑝! + 𝑒! + 𝜈 + 𝐸 Eq. 1.12 
An electron and an antineutrino is ejected from the nucleus and carry away the energy in 
form of kinetic energy. The kinetic energy released is shared between the neutrino and electron. 
The antineutrino is a weakly interacting elementary subatomic particle that undergoes essentially 
no interactions with matter and is practically undetectable. The energy for the beta-minus forms 
a spectrum, in which the mean energy may be approximated by 𝐸! ≈    (1/3)𝐸!!"# . The 
maximum beta energy for 142Pr is 2.162 MeV and its average beta energy is 0.809 MeV. In the 
standard nuclear notation, this decay is represented as: 
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𝑃𝑟!"!"# !! 𝑁𝑑!"!"#  Eq. 1.13 
The parent isotope and daughter are different elements with same mass number A. This 
decay is therefore an isobaric decay mode that results in a transmutation of elements. The 
daughter 142Nd is a stable nuclide. In the electron capture mode (0.0164%), one orbital electron is 
captured by the nucleus and combines with a proton to form a neutron: 
𝑝! + 𝑒! → 𝑛 + 𝜈 + E Eq. 1.14 
in the standard nuclear notation, this decay is represented as: 
𝑃𝑟!"!"# !" 𝐶𝑒!"!"#  Eq. 1.15 
This is an isobaric decay that also results in a transmutation of elements. The daughter 142Ce is 
also a stable element. 
1.9 Radionuclide Production 
Production mode of 142Pr may be achieved by either fast neutron activation or thermal 
neutron activation of 141Pr. The amount of activity produced in a sample irradiated with a particle 
beam will depend on the number of nuclei being irradiated, the flux of neutrons hitting the 
sample and the probability of interaction of the neutron with the atoms. The probability of 
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interaction is represented by the activation cross-section σ (barn). When the sample is irradiated 
with a constant neutron flux ϕ, the activity builds up from zero and approaches a saturation 
activity in which the nuclide disintegration rate is the same as the production rate. The saturation 
activity (Bq) of the material is given by: 
𝐴!"# = 𝑁𝜙𝜎 Eq. 1.15 
where N is the number of atoms in the sample, given by: 
𝑁 = 𝑚𝑁!𝑀  Eq. 1.16 
with m being the sample mass, Na the Avogadro’s constant (6.022 × 1023 mol-1) and M the 
nuclide atomic mass (140.9 g for 141Pr).  Equation 1.15 describes the sample saturation activity 
(Bq) for the cases where the nuclide is 100% abundant in the irradiated sample. If the isotope is 
not 100% abundant then the saturation activity should be reduced by the nuclide abundance 
percentage. The irradiated sample must be sufficiently thin in order for Eq. 1.15 to hold. If the 
sample is significantly thick, the neutron flux may be attenuated as it penetrates the target. The 
mass of the irradiated samples for the present work were small (0.169 g for the microspheres and 
0.35 g for each glass rod) and therefore Eq. 1.15 was used. Details of the sample sizes and 
dimensions used are discussed in CHAPTER 3: MATERIALS AND METHODS II:  
EXPERIEMTNAL DESIGN. The dependency of the activity on the irradiation time is given by: 
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𝐴 𝑡 = 𝐴!"#(1− 𝑒!!") Eq. 1.17 
where λ is the decay constant of the product nuclide. 
𝜆 = 𝑙𝑛  (2)𝑇!/!  Eq. 1.18 
and T1/2 is the radionuclide’s half-life. The calculated activation times and total activities are 
presented in CHAPTER 4: RESULTS. 
1.10 GAFCHROMIC® EBT2 Dosimetry Film 
Film dosimetry is a powerful tool for radiotherapy treatment verification and quality 
assurance. Over the years there have been significant improvements in the sensitivity and 
uniformity as two-dimensional detectors (Devic, 2011). Recently, film dosimetry has gained 
increased popularity in brachytherapy, diagnostic radiology, and radiobiological experiments. 
Two-dimensional arrays of diodes or ion chambers can produce results in real time, but film has 
the advantage of higher spatial resolution (25 µm). The spatial resolution of dosimeters is limited 
by the finite nature of dosimeter size and collecting volume. In the microscopic scale, the spatial 
resolution is limited by the stochastic nature of energy deposition in matter. GAFCHROMIC® 
EBT2 Dosimetry film is self-developing and does not require any film processing. It is energy 
independent, presenting minimal response differences from 100 keV into the MV range for both 
photons and electrons (Arjomandy, 2010). It is designed for quantitative dose measurements in 
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radiotherapy, and it is widely used in intensity modulated radiation therapy (IMRT) and 
brachytherapy, in which high dose gradients occur. It has also been shown that the dose response 
for GAFCHROMIC® EBT2 is independent of fractionation, dose rate and depth dependence in 
electron beams (Gerbi et al., 2009). The EBT2 film has near-tissue equivalent electron density 
(ZEBT2eff = 6.84 compared to Zwatereff = 7.3). Also, it is water resistant, and can be immersed for 
hours in water phantoms. It is stable in room light and temperatures up to 60 ºC.  
GAFCHROMIC® EBT2 film (Figure 1.1) is comprised of a single 30 µm thick active 
layer coated on a clear polyester substrate of 175 µm and covered with a 25 µm adhesive layer 
topped with a 50 µm polyester overlaminate. The active layer contains marker dye and stabilizers 
that undergoes changes in color upon irradiation. The optical density of the film can be expressed 
as: 
𝑂𝐷 = 𝑙𝑜𝑔 𝐼!𝐼  Eq. 1.19 
where I0 is the intensity of light transmitted by the unexposed film and I is the intensity of light 
transmitted through the exposed film.  
The active layer incorporates a yellow dye, which enables multi-channel (RGB) dosimetry and 
decreases the UV and light sensitivity. The multi-channel feature allows analyzing red, green and 
blue channels separately. Each channel presents a different darkening response to the dose 
absorbed. For instance, the blue channel exhibits a low slope because the signal is dominated by 
a dose independent contribution. On the other hand, the red channel presents a high slope curve, 
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due to the strong dose dependence of the signal in this channel. Previous studies have shown that 
red-channel data calibration done at standard megavoltage electron energies yields the best 
accuracy regardless of the energy (Kairn and Aland, 2013). Red-channel was used for the dose 
calibration curve. Film sensitivity limits in the red channel goes from 1 cGy to 10 Gy.	  Dose can 
be derived from the optical density if the film is properly calibrated with an absolute dosimeter 
such as a NIST traceable ion chamber.  
	  
Figure 1.1 Cross-section of a GAFCHROMIC® EBT2 film sheet and view of the asymmetric 
structure (http://online1.ispcorp.com/_layouts/Gafchromic/ content/ products/ ebt2/ pdfs/ 
GAFCHROMIC EBT2 Technical Brief-Rev1.pdf.) 
1.11 Specific Aims 
The fundamental question in the current clinical practice of radiation therapy is how to 
balance the optimization of tumor control with the minimization of post radiation therapy 
complications for the patient. The use of beta-minus emitters in brachytherapy has been 
increasing for both benign and malignant tumors (Sedda et al., 2012), as it represents a more 
targeted radiation therapy. Physical characteristics of beta radiation, such as the short penetration 
in tissue, allow the deposition of high doses to small volumes, avoiding unwanted doses to the 
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surrounding healthy tissues. In this proposal the beta emitter Praseodymium-142 (142Pr) is 
studied. 142Pr is a dual beta-minus/gamma emitter with a half-life of 19.12 h.  It undergoes beta 
decay (96.3%), with maximum beta energy of Eβ- = 2.162 MeV and presents a gamma emission 
(3.7%) with energy Eϒ = 1.575 MeV. It also presents a high neutron absorption cross-section of 
parent (11.40 barn including meta-stable state). 142Pr microspheres and seeds have been 
previously proposed for the treatment of prostate cancer and arteriovenous malformation (Jung 
and Reece, 2008; Lee and Reece, 2005). 142Pr can be easily activated in research facilities or 
clinics equipped with a low neutron flux reactor such as the 1 Megawatt TRIGA (Training, 
Research, Isotopes, and General Atomics). Two innovative applications for this radionuclide are 
presented: 142Pr Glass Microsphere brachytherapy for treating Hepatocellular Carcinoma (HCC), 
and a novel 142Pr eye applicator for treating Ocular Squamous Cell Carcinoma (OSCC). 
The overall goal of this work is to study the radionuclide 142Pr as a brachytherapy source, 
covering the possible benefits and issues related to the use of this beta emitter in microsphere 
brachytherapy and eye plaque brachytherapy, as well as propose a new device for dosimetric 
studies of dose distribution due to this nuclide. Both MCNPX2.6 Monte Carlo simulations and 
experimental measurements of the proposed brachytherapy sources were performed. Detailed 
radiobiological studies of the biological effects of this high dose rate nuclide in tissues and 
organs are studied using the well-known Linear Quadratic (LQ) Model (Armpilia et al., 2003). 
Specific applications of this radionuclide are (i) 142Pr microsphere brachytherapy for treating 
HCC and liver metastasis (ii) 142Pr glass eye applicator, an innovative device for brachytherapy 
of OSCC.	   	  
CHAPTER 2: MATERIALS AND METHODS I: THEORY AND SIMULATIONS 
2.1 142Pr MICROSPHERE BRACHYTHERAPY 
2.1.1 Clinical Activity and Tumor Target Dose 
Source activity for TheraSphere® (90Y glass microsphere) is calculated based on the 
nominal target dose and patient’s liver mass (Kennedy et al., 2007). The treatment prescription 
dose considered for brachytherapy is between 120 to 180 Gy. In this study a dose of 150 Gy was 
considered for calculation and simulation purposes. The same total physical dose was considered 
for 142Pr and 90Y in order to compare the effects for a fixed dose. 
2.1.2 Physical and Radiobiological Properties 
Several physical and radiobiological aspects, including physical half-life, dose 
distribution and biological effective dose for 142Pr and 90Y were also compared in this work. 
Table 2.1 and 2.2 list the properties of beta emitters and the composition of rare earth 
aluminosilicate (REAS) and yttrium aluminosilicate (YAS) glasses. The time to deliver 90% of 
the dose (T90) for 142Pr (2.65 days) is approximately 30% of T90 for 90Y (8.86 days). This is one 
advantage of 142Pr over 90Y, since the longer the treatment time the higher is the risk of dose 
contamination to healthy tissue due to migration to adjacent organs (especially to lungs)  
(Kennedy et al., 2007). 142Pr rare earth REAS glass is composed of 15.5% Silica, 8.1% 
Aluminum, 44.5% Praseodymium, and 32.1% Oxygen.   
	   29	  
 
 
Table 2.1: Physical properties of beta emitters used in microsphere brachytherapy (Häfeli, 2001) 
Property 142Pr 90Y 32P 
Half life 19.12 h 64.0 h 342.7 h 
Time to deliver 90% of the dose 2.65 days 8.86 days 47.4 days 
Maximum beta energy (MeV) 2.162 2.281 1.709 
Average beta energy (MeV) 0.809 0.934 0.695 
Maximum Range in Tissue† (mm) 10.3 10.9 7.90 
Density of glass (g/cm3) 4.0 3.29 3.06 
Gamma emissions for imaging 
Brems§  
1.58 MeV, γ(3.7%) 
Brems§ Brems§ 
Thermal neutron cross section 7.5 b (+3.9 b)¥ 1.28 b 0.17 b 
†	  Calculated using Eq. 1.11 (Katz and Penfold, 1952). 
§ Bremsstrahlung. 
¥ Cross section of meta-stable state. 
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Table 2.2: Composition of 142Pr and 90Y glass microspheres. 
Element 142Pra 90Yb 
Si 0.153 0.194 
Al 0.081 0.106 
Pr 0.445 0 
Y 0 0.303 
O 0.321 0.397 
Total 1.000 1.000 
a Composition of 142Pr REAS glass (Jung and Reece, 2008) 
b Composition of 90Y YAS glass (Poorbaygi et al., 2011)  
	   31	  
Radiobiological Effective Doses for 142Pr and 90Y  
A numeral software package, Mathematica® 8 (Wolfram Research, Champaign, IL) was 
used to perform the BED calculations. BED values for both 142Pr and 90Y given different values 
of HCC clonogenic doubling times (DTs) were calculated. BED varies with the radionuclide 
properties, the tumor radiobiological factors and the tumor DT. HCC doubling times vary greatly 
according to the tumor types: well, moderately or poorly differentiated. The rate of tumor growth 
can be classified as: slow (DT > 100 days); intermediate (50 days < DT < 100 days); or rapid 
(DT < 50 days). The distribution of DT values within each group is positively skewed, with 
some tumors presenting very long DT values compared to the mean value. For this reason, 
ranges of values were considered for BED calculation, rather than using mean values. DT values 
for each group were classified as: well differentiated (38-720 days), moderately differentiated 
(17-380 days) and poorly differentiated HCCs (20-70 days), based on clinical values obtained in 
previous studies (Mehrara et al., 2007). An α/β value of 10 Gy (tumoral liver), and a total 
physical dose (PD) of 150 Gy was used for both radionuclides. A total physical dose (PD) of 10 
Gy and an α/β value of 2.5 Gy was used for the healthy liver tissue, based on α/β values 
previously reported in the literature (Cremonesi et al., 2008). Total time to deliver 90% of the 
prescribed dose was estimated for 90Y and 142Pr by calculating the total time from the 
microsphere embolization procedure up to the time that only 10% of the initial activity is 
remaining in the patient’s system. A total physical dose (PD) of 150 Gy was considered for both 
radionuclides studied. The initial dose rate R0 was calculated by dividing the total physical dose 
by the mean life of the nuclide. Comparison between the total times to deliver 90% of the 
prescribed total dose of 150 Gy was also performed for 90Y and 142Pr. 
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2.1.3 MCNPX2.6 Monte Carlo Simulations 
Praseodymium-142 versus Ytrium-90 
In order to evaluate the feasibility of 142Pr in microsphere brachytherapy, we analyzed 
dose distribution using MCNPX2.6, BRAIN-DOSE code and analytical calculations and 
compared with the dose distributions produced by 90Y. Figure 2.1 shows the beta spectrum for 
142Pr and 90Y (Cross et al., 1983) used for the MCNPX2.6 source energy input.  
 
Figure 2.1 142Pr and 90Y Beta energy spectrum used for MC simulation. 
Calculations using BRAIN-DOSE code (Dauffy, 1988), based on dose point kernel (DPK) 
method, and simulation using MCNPX2.6 Monte Carlo (MC) code of dose rates due to 142Pr and 
Pr-142 and Y-90 Beta Spectrum
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90Y point sources were performed. MCNPX2.6 code simulations were performed on a computer 
with the following specifications: RAM: 12GB; CPU: Intel(R) Xeon(R), 12 Cores; OS: Linux 
Ubuntu 64 bit. Several physical and radiobiological aspects, including physical half-life, dose 
distribution and biological effective dose for 142Pr and 90Y were also compared. 
Dose distribution for a point source 
DPK calculation and MC simulation were also performed to determine the dose 
distribution due to a 142Pr point source. Dose rate for 90Y was calculated using DPK method and 
the results were compared with the benchmarked calculations from Berger, presented in the 
previous work from Vynckier and Wambersie (1982). Results from DPK calculations were 
compared with MC results. Dose rates produced by 142Pr and 90Y point sources were also 
calculated using the DPK method and compared at 0.5 cm away from the point sources. 
Dose distribution for a spherical ensemble of microspheres 
MCNPX2.6 code was used to simulate the dose delivered by a given ensemble of 
homogeneously distributes microspheres within a tumor for both beta and gamma contributions 
for 142Pr and for beta contributions for 90Y. A spherical tumor immersed in water was used in this 
model. The tumor size was based on the average reported sizes found in the literature with radius 
ranging from 1 to 5 cm (Sarfaraz et al., 2003). MCNPX2.6 was used to model the geometry of 
the glass microspheres distributed within the tumor for different tumor sizes and volume of 
surrounding water (input code can be found in Appendix A.1.1). The source was defined using 
the source definition (SDEF) parameters in MCNPX2.6. The source was uniformly distributed 
within the spherical shape. Details of the radionuclide, such as beta energy spectrum, glass 
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density and percent weight composition were also entered as parameters for the source definition 
coding. Number of source electron histories and statistical uncertainties were chosen so that there 
was less than 1.50 % statistical error for the points of interest. Three-dimensional mesh-tallies 
were defined to cover the total tumor volume and extra margin was given to access the dose 
deposited in the tumor vicinity. Dose rate calculations for the gamma contribution were also 
performed using MCNPX2.6 simulation and the analytical equation. The differences in the code 
for modeling the gamma component consist in changing the particle type that the MC code will 
track, from electron (E) to gamma (P), and changing the mesh tally distance ranges, since the 
gamma rays are more penetrating than electrons. The source definitions and geometries used for 
gamma modeling were the same as used for the electron code.   
Dose distribution for cylindrical blood vessels  
Dose distributions of microspheres within a single blood vessel were simulated in this 
paper. Post treatment liver analysis has shown that the highest concentration of microspheres is 
deposited at the tumor boundaries and blood vessels (Sarfaraz et al., 2004; Fox et al., 1991). The 
microspheres are embolized especially well within the tiny blood vessels surrounding the tumor 
surface, responsible for providing blood supply to the tumor. Dose distribution due to 90Y and 
142Pr within blood vessels was simulated using MCNPX2.6 (input code can be found in 
Appendix A.1.2).  
This model uses cylindrical blood vessels with diameters ranging from 25 to 75 µm 
(diameters based on the average sizes reported by Kennedy et al., 2004), with a length the same 
as the tumor diameter. Blood vessels were modeled as a cylindrical volume source. The 
radioisotope was uniformly distributed within the volume sources, and located in the center of a 
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0.2, 0.5 and 1.0 cm radius tumor. Figure 2.2 shows the model of a 50 µm diameter blood vessel, 
both within and at the periphery of a 0.5 cm tumor radius. A total activity of 8,400 Bq and 2,500 
Bq was used per microsphere of 142Pr and 90Y, respectively. 
 
 
Figure 2.2 Model of a blood vessel inside and at the periphery of a 1 cm tumor. Microspheres 
are embolized within the 50µm blood vessel. 
These activities resulted in the same number of disintegrations for both nuclides during 
entire treatment period. The same number of disintegrations was chosen in order to calculate the 
total physical dose delivered by each radionuclide, for the same number of decays.  
The same number of microspheres was considered for both nuclides, i.e. 1.2 × 106 
microspheres per vial (Kennedy et al., 2007), which equates to an activity of 3 GBq for 
TheraSphere®. In order to deliver the same physical dose, an activity of 10.1 GBq would be 
required for the 142Pr vial. The 142Pr gamma component may raise concerns regarding the 
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radiation protection of the dose due to its 3.7% gamma component. However, the specific 
gamma-ray dose constant, Γ, for 142Pr (8.050 × 10-6 mSv h-1 MBq-1) is considerably smaller than 
Γ for other nuclides used in nuclear medicine and therapy, such as 11C (1.937 × 10-4 mSv h-
1 MBq-1) and 137Cs (1.032 × 10 -4mSv h-1 MBq-1) at 1 meter from the source (Unger and Trubey, 
1982). The ambient dose rates for 142Pr were calculated for a point source and compared with the 
limits for occupational and general public exposures. 
The physical dose distribution for each case was simulated. However, in order to 
compare the efficacy of the treatment, the biological effective dose (BED) should be also taken 
into account. Therefore a Biological Effective Dose Volume Histogram (BEDVH) (Gagne et al., 
2012) was plotted for each case studied, in order to determine the percent volume of the tumor 
receiving biological effective dose higher than 150 Gy. The target dose prescribed for 
microsphere brachytherapy is between 120 to 180 Gy (Dezarn et al., 2011), therefore 150 Gy 
was chosen to represent the average treatment target dose. 
Dose distribution for microspheres within a glass capillary 
In order to compare the MCNPX2.6 Monte Carlo simulations with the experimental 
design, a glass capillary immersed in water and filled with 142Pr glass microspheres was modeled 
in MCNPX2.6 (input code can be found in Appendix A.1.3). The capillary had an internal 
diameter of 305 µm and external diameter of 453 µm, which are the same dimensions of the 
glass capillary used in the experiments. The modeled glass vial had the same averaged 
dimensions of the capillary used in the experimental section and is described in CHAPTER 3: 
MATERIALS AND METHODS II: EXPERIMENTAL DESIGN. Glass composition of the 
capillary was taken into account in this simulation and it was the same used for the Monte Carlo 
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experimental validation. The following chemical composition (weight percent) was used: 74%: 
SiO2, 13%: Na2O, 10.5%: CaO, 1.3% Al2O3, 0.3% K2O, 0.2%: SO3, 0.2%: MgO, 0.04%: Fe2O3, 
0.01: TiO2.The experimental setup for accessing the dose distribution using GAFCHROMIC® 
EBT2 film due to a single glass capillary is described in Chapter 4: EXPERIMENTAL DESIGN. 
The dose deposited per decay was analyzed in a set of 60 × 60 × 60 voxels distribute in the x, y, 
and z-axis. The total volume analyzed around the capillary was 5 × 5 × 5 mm3. Each voxel had a 
total volume of 1.157 µm3. 
2.1.4 Analytical calculations for gamma dose distribution 
The analytical modeling for the total dose takes into account the inverse square law and 
attenuation contributions. Volume integrals to determine the total dose were solved using 
Mathematica software. The photon fluence differential 𝑑𝜙 at a given point 𝑎 outside the tumor, 
due to a volume differential dV is given by:  
𝑑𝜙 = 𝛾!𝐴!𝑒!! ! 𝒓!𝒓! !4𝜋 𝒓− 𝒓! ! 𝑑𝑉 Eq. 2.1 
where 𝛾! is the gamma yield, 𝐴! is the volume density of activity (total activity/volume), 𝜇 𝜌 
the mass attenuation coefficient for a given photon energy, 𝒓′ is the vector representing the 
position of the fluence differential shown in Figure 2.3, 𝒓 is the vector representing the position 𝑎 outside the tumor, |𝒓− 𝒓′| the distance between the source differential and the point of 
interest  𝑎, and 𝜌 is the medium density.  
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Figure 2.3 Geometry used for analytical calculations. Tumor is filled with activated 142Pr 
microspheres and immersed into the water. 
The dose rate differential at the point of interest  𝑎 is given by: 
𝑑𝐷 = 𝐸  𝑑𝜙 𝜇!"𝜌  Eq. 2.2 
where 𝐸 is the photon energy, 𝑑𝜙 is defined in Equation 2.1 and 𝜇!" 𝜌 is the mass energy 
absorption for a given photon energy. The total dose rate 𝐷 at the point of interest  𝑎 can be 
calculated by integrating the dose rate due to each fluence contribution over the entire spherical 
volume. In spherical coordinates it becomes: 
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𝐷 = 𝐸   𝜇!"𝜌   𝛾!𝐴!𝑒!! ! 𝒓!𝒓! !4𝜋 𝒓− 𝒓! ! 𝑟!𝑠𝑖𝑛𝜃  𝑑𝑟  𝑑𝜃  𝑑𝜑 Eq. 2.3 
With 𝑟 varying from 0 to R, 𝜃 from 0 to 𝜋, and 𝜑 from 0 to 2𝜋. The dose was calculated for 
different values of 𝑎 along the x axes. For instance, for a 1 cm radius tumor the dose rate was 
calculated for x values ranging from 0 to 10 cm. Total activity was 10.1 GBq for 142Pr 
calculations, based on the typical vial activity used for 90Y treatments. The energy absorption and 
mass attenuation coefficients used for tumor and medium were those of water for a 1.58 MeV 
gamma photon. Comparison between the time to deliver 90% of the prescribed dose was 
performed for 90Y and 142Pr. Results were compared with values obtained from the simulation.  
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2.2 CONFORMAL EYE BRACHYTHERAPY DEVICE  
2.2.1 Device development 
The development and design of a conformal eye brachytherapy (CEBT) device for an 
individualized treatment of OSCC using 142Pr is proposed and studied. This study is divided into 
two main steps. The first step identifies (i) the rational for and importance of a new eye 
applicator, and (ii) the device design and how it compares to the currently available eye plaques. 
The second part consists of the preliminary studies on the viability of a new eye applicator, 
which consists of: (i) the evaluation of several possible radionuclides (ii) MCNPX2.6 Monte 
Carlo simulations for the proposed geometry and radionuclide comparison, and (iii) experimental 
validation of the Monte Carlo method for a simplified case. Future work includes patent 
application, device assembly, development of a treatment planning system capable of calculating 
the necessary fields in order to optimize the tumor coverage, and proposing quality assurance 
(QA) methods to verify the treatment planning and dose delivered. 
Choice of radionuclide 
In previous work the use of beta emitters 90Y and Rhenium-188 (188Re) has been reported 
for eye brachytherapy. Based on its physical and radiobiological properties, as well as its 
availability and activation costs, 142Pr was chosen as a suitable radionuclide for this study. 
However, the device design is not limited to this radionuclide and other beta emitters could be 
used as well. Monte Carlo simulations were performed to determine the beta and gamma dose 
distributions for 142Pr within the eye. Simulation of dose distributions for 90Y and 188Re were 
performed as well and compared with the distribution for 142Pr 
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2.2.2 CEBT design 
An average adult human eye has an axial length along the visual axis of 24 mm, 
horizontal and vertical diameters of 23 and 23.5 mm and a mass of 7.5 g. The proposed device is 
able to cover up to 3 cm diameter of a spherical surface. The device consists of 142Pr glass rods 
arranged in a 3.00 cm diameter grid, capable of covering most scleral tumor sizes. Individual 
rods can be controlled independently. Figure 2.4 shows the device and ten selected rods 
projected outside of the beta shield. 
 
Figure 2.4 Eye applicator design. 
The device was drawn using the 3D Computer aided design software, SketchUp Version 
8. A digital control system, connected to a computer interface, would allow the execution of the 
treatment plan. The rods are placed parallel to each other within a hexagonal template. The 
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motion of each rod is independent, allowing the positioning of any combination of rods on the 
eye surface. The length of the rod projection can be also controlled in order to better conform to 
the spherical shape of eye surface. The surrounding external case and template are made of a 
beta shielding material, e.g. Plexiglas. The device holder was designed to rotate and translate to 
allow better positioning of the eye device on the patient eye surface (Figure 2.5). 
 
Figure 2.5 Eye applicator holder 
The patient head and eye may be immobilized prior to the treatment, to allow a precise 
delivery of the total planned dose. Four different “segments”, formed by configurations of glass 
rods, and the resultant “field” is shown in Figure 2.6, with the rods used for each field 
highlighted. The freedom of independently positioning the rods would allow a more conformal 
	   43	  
dose to be delivered to the tumor. Computer programmed rod placement would allow a set of rod 
configurations to deliver the planned dose. 142Pr can be activated immediately before use in a 
research reactor such as TRIGA. This device can also be reactivated several times and therefore, 
eye applicators using this nuclide could be reused upon nuclide reactivation.  
Materials selected for the device’s prototype 
A prototype of the eye device was developed in the East Carolina University Physics 
Department machine shop, and is in the initial execution phase. The materials selected for the 
core of the CEBT in this first model was Self Lubricating Oil-Filled UHMW (Ultra High 
Molecular Weight) Polyethylene, with 1-1/4" Diameter, and 1' length from McMaster-Carr 
Supply Company. This material was chosen for its desirable physical properties. For the movable 
rods High Temperature Garolite (G-11), 1/16" Diameter, and 1' Length was chosen. 
2.2.3 Monte Carlo Simulation for CEBT device 
A glass rod was simulated (Figure 2.7) to determine the dose distribution within the 
eyeball for the use in episcleral brachytherapy using MCNPX2.6 Monte Carlo code (input codes 
can be found in Appendix A.2.1 and A.2.2). Dose due to one rod can be used to derive the dose 
due to an arrangement of rods by the superposition principle. A total physical dose of 85 Gy was 
used as reference dose in the treated tumor volume, based on the American Brachytherapy 
Society (ABS) recommendations for brachytherapy of uveal melanomas (Nag et al., 2003). 
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2.2.4 MCNPX2.6 Monte Carlo Simulations for 142Pr, 90Y, and 188Re 
In order to compare 142Pr, 90Y and 188Re as possible choices for use in eye brachytherapy, 
Monte Carlo simulations were performed for each nuclide to determine the dose distributions 
within the eyeball (input code can be found in Appendix A.2.3).  A model for the glass eye 
plaque applicator was designed for episcleral brachytherapy, with rectangular geometry of 1.00 × 
1.00 cm2 area and curved interior (Figure 2.8). The eye applicator was designed to contour to the 
eye and to be in contact with the eye surface during the treatment. This geometry, contrary to the 
model proposed for the CEBT, delivers a more homogeneous dose to the eye surface. However 
the goal in these simulations was to compare the effect in the eye doses when different nuclides 
are used, and therefore a simpler geometric model was adopted. 
A total physical dose of 85 Gy was used as reference dose in the treated tumor volume, 
based on the American Brachytherapy Society (ABS) recommendations for brachytherapy of 
uveal melanomas. From the nuclides studied, 188Re had the highest parent isotope cross-section 
(73 b), followed by 142Pr (11.4 b) and then 90Y (1.28 b). The half-life of 188Re was the shortest 
(17.0 h), compared to 90Y (64.0 h) and 142Pr (19.12 h).  
A last model for the eye rod MCNPX2.6 Monte Carlo Simulations (input code can be 
found in Appendix A.2.4) was developed simulating the experimental measurements conducted 
with 142Pr glass rods in water phantom. A squared water phantom (red) was used to simulate the 
measurements conditions (Figure 2.9). The 1.5 mm diameter eye rod (blue) was placed on top of 
the water phantom. Both 142Pr glass rod and water phantom were surrounded by air (green). A 
mesh tally containing 60 × 60 × 60 voxels was created and the dose profile was analyzed in the 
xy-axis and zy-axis, in a squared volume of 1.0 cm3.  
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Figure 2.6 Top view of the eye applicator: rods are allowed to move independently in order to 
conform the particular target geometry being treated and to deliver the planned dose. In this 
figure we can see different segments added together (a) no rods (al green), (b) one (yellow), (c) 
two (yellow + orange), (d) and three (yellow + orange + red) segments added to form a field.  
(a)	   (b)	  
(c)	  
(d)	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Figure 2.7 Eye model and one 142Pr rod touching the eye surface (sclera). A total dose of 85 Gy 
was used as a reference in the treated tumor volume, according to the ABS recommendations for 
brachytherapy of uveal malanomas (Nag et al. 2003). Credits for the model for detailed anatomy 
of the eye in MCNPX2.6: Choonsik Lee, PhD, National Cancer Institute. 
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Figure 2.8 Sagittal view of the geometry input used in the MCNPX2.6 to simulate the dose 
distribution due to 142Pr, 90Y and 188Re within the eyeball. Eye plaque (blue), the eyeball (red) the 
eyeball surroundings (green) and the air outside the body (white).  
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Figure 2.9 Geometry input used in the MCNPX2.6 to simulate the dose distribution due to 142Pr 
experiments with glass rods. The squared water box (red) had dimensions 2.5 × 2.5 × 2.5 cm3, 
the rod (blue) had the same dimension of the experimental glass rod, 1.5 mm diameter and 5 mm 
length. Dose profiles were acquired on the plan perpendicular to the base of the rod and on the z-
axis, parallel to the rod’s symmetry axis.  
CHAPTER 3: MATERIALS AND METHODS II: EXPERIMENTAL DESIGN 
3.1 Microsphere Brachytherapy and Eye Brachytherapy 
In this chapter the experimental techniques to measure the dose fall-off due to the 142Pr 
glass microspheres and 142Pr glass rods are described. Dose distributions in custom designed 
solid water phantoms were measured using GAFCHROMIC® EBT2 film. Details of the phantom 
design and film calibration, as well as safety measures involved in these measurements are 
described in this chapter. 
3.2 Nuclide Activation 
142Pr Microspheres Activation 
The 0.169 g sample of 141Pr microspheres was irradiated and the calculated activity at the 
time of receiving the source was 36.6 mCi. The measurements were performed on the same day 
the microspheres were received. For a clinical vial activity of 7,500 Bq per 142Pr microsphere, 
containing a total of 1.2 × 106 microspheres, the vial activity would contain 9 GBq or 2.43 Ci. 
The final activity of the sample was scaled down from the necessary clinical activity so that the 
radiation exposure to the staff and general public could be minimized. The reactor used for 
irradiating the samples was the Missouri University Research Reactor (MURR®) with a neutron 
flux ϕ of 9.60 × 1013 thermal n(cm2s)-1. The total irradiation time was 0.40 h (24 min), and the 
time from the irradiation time until sample delivery was approximately 33 hours. Samples were 
shipped to the Radiation Safety Officer and transported to the East Carolina University main 
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campus. The experimental setup and measurements were performed in the Health and Medical 
Physics Lab facilities at the Howell Science Complex, East Carolina University. 
The percentage of 141Pr in the microspheres used was 46.14 %. Therefore, the number of 
atoms N, contained in 0.169 g of 141Pr calculated using Eq. 1.16 (reduced to 44.4%) was 
3.20 × 1020, with m equal to 0.169 g and M equals to 141 g/mol. The saturation activity of this 
sample calculated using Eq. 1.15 was 3.57 × 1011 Bq (9.64 Ci), with ϕ equals to 9.60 × 1013 
thermal n(cm2s)-1, σ equals to 11.6 × 10-24 cm2, and N equals to 3.20 × 1020. Therefore, the 
activity (Ci) as a function of the time for the 0.169 g of 141Pr microspheres sample is: 
𝐴 𝑡 =   9.64  (1− 𝑒!(!.!"#$)!) Eq. 3.1 
where t is the irradiation time in hours and 0.0361 (h-1) is the calculated decay constant for 142Pr. 
To obtain the irradiation time (h) as a function of the desired activity of this sample, this equation 
can be rewritten as: 
𝑡 =   27.7  𝑙𝑛 1− 𝐴9.64 !! Eq. 3.2 
To obtain 36.6 mCi at the delivery time the sample should be irradiated by 0.4 h (24 min). 
 
	   51	  
142Pr Rods Activation 
Ten 141Pr glass rods were activated in the same research reactor. The glass rods had 
diameter of 1.5 mm and a length of 5 mm, with a total sample mass of 0.353 g. They were 
composed of 44.5% of 141Pr. Using the same calculation methods described for the microspheres 
sample, the received activity for each rod was calculated as 76.3 mCi. 
3.3 Experimental Setup  
A phantom was designed and constructed to carry out the dose distribution 
measurements. Measuring dose of a single microsphere is challenging, due to its small size and 
limitation of the total dose delivered by a single sphere. Unlike other sealed sources used 
routinely in brachytherapy, the activity and dose due to a single microsphere cannot be 
individually verified. In fact, no standardized methods exist to this date to verify 90Y microsphere 
vials activities (Dezarn and Kennedy, 2007; Dezarn et al., 2011). Therefore, the measurements 
with microspheres were performed in bulk solution distributed in a known geometry. A micro 
glass capillary was used to hold the microspheres. Having a known geometry made possible to 
validate the Monte Carlo simulations with the experiments. The detailed experimental setup and 
procedures to perform these measurements will be discussed in the following sections. 
3.3.1 Film Calibration 
The change in optical density of the irradiated GAFCHROMIC® EBT2 calibrated film 
was used in this work to access the dose fall-off of due the 142Pr microspheres and to the 142Pr 
glass rods. For the film calibration, known doses of electron external beam calibrated by the 
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TG51 protocol were used to irradiate the film. An Exradin Farmer-type chamber Model A12 was 
used for the output check. This ion chamber is specifically designed for absolute dosimetry 
calibrations in water, air, or other phantom material and it is completely characterized in TG 51 
(Almond et al., 1999). A 6 MeV electron beam (Siemens ONCOR™ Linear Accelerator, Leo 
Jenkins Cancer Center) was used to calibrate the GAFCHROMIC® EBT2 film. The beam output 
was measured at 1 cm depth in solid water, with 100 cm source to surface distance (SSD), 
collimated with a 15 × 15 cm2 cone, which corresponds to the machine calibration point. The raw 
reading was corrected for the temperature and pressure and then compared with the calibration 
value. The temperature and pressure correction factor is given by: 
P!" = 273.2+ T273.2+ 22.0× 760P  Eq. 3.3 
Where T is the temperature in degrees Celsius and P is the pressure in mmHg. For the 
temperature measurement, a thermometer was placed inside the solid water phantom and stayed 
for a few minutes until reaching thermic equilibrium. Temperature and pressure values of 22.4 
ºC and 769 mmHg were measured, and a value of 0.990 was calculated for PTP. The calibrated 
reading for the 6 MeV electron beam obtained from the annual quality assurance was 20.86 × 10-
9 C. The corrected reading using a NIST calibrated Exradin A16 ion chamber was 20.78 × 10-9 C, 
or 0.383% lower than the calibrated value. Therefore the dose per monitor unit (MU) was 
corrected by 0.383%. A total of 11 stripes having 2 cm × 3 cm were exposed to doses ranging 
from 0 to 1020 cGy. One additional stripe of the film was left un-irradiated and used as a 
reference for the scanned output corrections. The number of MUs delivered to the film stripes 
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were: 0, 20, 40, 80, 160, 240, 320, 420, 520, 620, 820, 1020 MUs. Only one film stripe was 
irradiated at a time, in order to have them placed in the same position in relation to the field size. 
Each film was placed at the center of the field size, where the beam is more symmetric and flat. 
Films were places at depth of dmax (1.3 cm). After temperature and corrections were applied, a 
1.0038 cGy/MU was found for the beam output at dmax. 
GAFCHROMIC® EBT2 film has an asymmetrical cross-section and also a directional 
dependence for portrait or landscape orientation. Therefore, each stripe of film was marked with 
a slit in the top right corner, following the original film sheet to guarantee that every individual 
stripe would be scanned in the same direction. 
After 24 hours of the exposure, the color changes in the film were read using a flatbed 
Epson Perfection V750 Pro scanner (Leo Jenkins Cancer Center). Digital images of the film 
stripes were acquired according to the scanning guidelines suggested by the GAFCHROMIC® 
EBT2 manufacturer. Readings were done using a 48-bit color image type, with resolution of 300 
dpi, and with all the image adjustment features turned off. Images were analyzed using the public 
domain software, ImageJ (Image processing and analysis in Java) developed at the National 
Institute of Health (NIH). The RGB channels were split (Figure 3.1) and each channel was 
converted to a 16-bit gray scale. Gray values ranged from 0 to 255, in which values closer to 0 
correspond to more exposed areas. A histogram function was used to analyze the film gray 
scales.  
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Figure 3.1 Red Blue Green Channels and their different brightness responses to radiation doses.  
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Figure 3.2 Film calibration using a Siemens ONCOR 6 MeV electron beam: gray-scale plot of 
the RGB channels and fitted curves.  
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An average of 30,000 pixels was counted in each film stripe. Values for maximum, 
minimum, median and average gray scale values were acquired in ImageJ and plotted using 
SigmaPlot™ software (Figure 3.2). Standard deviations for gray scale values were within ±1% 
and therefore were not included in the plot. A non-linear regression and dynamic fitting was 
performed using SigmaPlot™ software. A three-parameter exponential decay equation was used 
to fit the red channel gray scale plot: 
𝑓 = 𝑦! + 𝑎𝑒!!" Eq. 3.4 
with parameters equal to: y0 = - 47.94 ± 8.61, a = 4661.1 ± 158.3, b = 0.0242 ± 0.0006. A total of 
200 iterations was performed a R2 = 0.9994 was obtained for this dynamic fitting. 
3.3.2 Verification of Glass Microspheres 
The 141Pr glass microspheres (Figure 3.3) were manufactured by MO-SCI Corporation 
(Rolla, MO). The composition of the glass microspheres is as follows: Si: 12.5%, Al: 9%, Pr: 
46.14%, and O: 31.31%. The composition of the glass rods is very similar: Si: 15.3%, Al: 8.10%, 
Pr: 44.5%, and O: 32.1%. According to the manufacturer, microspheres sizes range from 20 to 
35 µm. The inactive microsphere sample was analyzed using an optical microscope (Nikon, 
TE2000-S) in order to estimate the average size of the microspheres in the sample. Several 
frames at different parts of the sample were taken.   
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Figure 3.3 Inactivated Pr glass microspheres  
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Figure 3.4 Microscopic view of the 141Pr microspheres 
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A total of 8 frames from different regions of the sample were analyzed (Figure 3.4). The 
first frame contains the microscope ruler with marks from 0 to 100 µm, with resolution of 2 µm, 
used for the pixel calibration. ImageJ software was used to determine the number of pixels 
corresponding to 100 µm so that a conversion between number of pixels and actual size could be 
determined. It was found that at the imaging magnification, 751.41 pixels was equivalent to 100 
µm, or 0.1331 µm/px. A total of 70 microspheres were measured. Only microspheres positioned 
at the same level as the focal distance of the microscope were taken into account, due to the 
optical artifact of a thicker and blurrier border for the microspheres out of focus. An average 
diameter of 29.7 µm with standard deviation of 3.9 µm was found for this sample. 
3.3.3 Experimental setup for accessing dose fall-off of microspheres 
As discussed earlier, dose assessment of individual microspheres may be limited by their 
physical size and also by the small activity of a single microsphere. Arterioles have an 
approximated size of 37.0 µm, and the end of capillary bed ranges from 8 to 10 µm. Ideally, an 
experimental setup capable of representing an embolized blood vessel should have dimensions 
comparable to that of a blood vessel. However, due to experimental limitations of smaller sizes 
and lower doses measurements, handling and performing dosimetry for such small dimensions 
were unpractical. To overcome these limitations, a larger system was proposed to hold a bulk of 
microsphere solution.  
A glass microcapillary (Drummond Scientific Company, Broomall, PA) was used to hold 
a dense microsphere solution (Figure 3.5). The microcapillary had inside diameter (ID) of 300 
µm and outside diameter (OD) of 450 µm. The R-6 glass, as known as Soda Lime, had the 
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following chemical composition (weight percent): 74%: SiO2, 13%: Na2O, 10.5% CaO, 1.3% 
Al2O3, 0.3% K2O, 0.2%: SO3, 0.2%: MgO, 0.04%: Fe2O3, 0.01: TiO2. 
	  
Figure 3.5 Glass capillaries used as receptacle of microspheres. 
The wall thickness of about 150 µm was still thin enough to allow beta dose penetration 
and dose assessment by the film placed outside of the capillary. The microsphere solution was 
transferred to the capillary interior by using a micropipette developed for this purpose (Figure 
3.6). 
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Figure 3.6 Micropipette developed to fill the glass capillary with the microspheres. 
Microcapillary was attached to a disposable plastic 1 ml pipette through a micropipette (yellow 
part in the figure). 
The solution was prepared by mixing 0.1 ml of sterile water (Cellgro®, Mediatec, Inc., 
Manassas, VA) to the activated microspheres. After filled with the microspheres solution, the 
capillary tips were sealed with super glue (Krazy Glue™). Based on the total volume inside the 
sample and concentration, a total of about 70,000 142Pr microspheres were inside the 
microcapillary. The final sample was analyzed under the microscope to access the pattern of 
microspheres distribution inside the micro capillary (Figure 3.7). 
A new phantom was developed for this research to suit the requirements of the 
measurements (Figure 3.8). In order to attain full backscattering conditions for both primary and 
secondary photons and electrons the glass capillary was surrounded in by water and water 
equivalent plastic. 
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Figure 3.7 Air-microcapillary-microphere solution interface under the microscope. 
Gammex Solid Water® was chosen as base material for this phantom. Solid Water® is a 
tissue equivalent material, and therefore, it has been used extensively for dosimetric purposes in 
medical physics, especially in IMRT dose assessment. One Solid Water phantom of 12 × 12 
squared inches and widths of 5 cm formed the base of the phantom. Two square frames of 
Acrylonitrile butadiene styrene (ABS) with 1/2 inch each were cut and joined together on top of 
the film and placed on the phantom.  
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Figure 3.8 Phantom developed to carry the measurements with the microspheres. A 
GAFCHROMIC® EBT2 film sheet (yellow line) was placed on top of a Gammex Solid Water® 
plastic slab. An external ABS plastic frame was placed on top of the Solid Water® phantom to 
support the liquid water. A plastic wrap (blue line) was used to protect the film from the water. 
Another internal ABS frame was used to hold the plastic wrap extended on top of the film. The 
internal frame was filled with water and the capillary containing the 142Pr microspheres was 
placed in the water.  
The ABS top frames were used to hold a plastic wrap placed against the film surface on 
the edges of the solid water phantom and did not have any influence on the radiation interactions. 
Although ABS was not used as a phantom itself in this work (because of the lack of published 
data on its electron stopping power), ABS has been used for IMRT QA. ABS is a plastic-based 
low cost tissue equivalent material, and it has been proven to have similar attenuation coefficient 
to that of the solid water for different photon energies (Rajesh et al., 2010). ABS is also impact 
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resistant and presents high toughness, while being easily machinable. It can be designed to hold 
several types of detectors, including ion chambers, radiochromic film, gel dosimeters, diodes, 
and TLDs.  
The film stayed in place for 51 hours (2.66 half-lives of the nuclide). The activity of the 
vial was measured using a NaI detector (NAIS-2x2 detector with Osprey™ digital tube, 
CANBERRA Industries, Inc.). Based on the sample total mass of 0.169 g, the glass density of 
4.0 g/cm3 and the measured average microspheres diameter sizes of 29.7 µm, volume of 1.38 × 
10-8 cm3, mass of 5.49 × 10-8 it was estimated a total of 3.08 × 106 microspheres in the sample. A 
standard 90Y glass microspheres sample (Therasphere®) supplied in a 0.6 ml of sterile, pyrogen-
free water usually contains from 22,000 to 73,000 microspheres. In this experiment 1.0 ml of 
distilled water was used to prepare the solution of microspheres. A final concentration of 3.08 × 
106 per ml was obtained. The remaining microsphere solution was deposited in a second water 
phantom, at spaced distances from one drop to the other. Once the microspheres reached the 
water phantom they formed random clusters that allowed measuring the dose distribution of 
microspheres distributed in different concentrations. 
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Figure 3.9 142Pr glass rods and DREMEL tool with diamond cut-off wheels (DW10M, SE®) was 
used to cut the rod into 5 mm length rods. Rod tips were smoothed until flat. 
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3.3.4 Glass Rods Measurements 
The glass rod was cut into sections using a DREMEL® tool with diamond cut-off wheel 
(Fig. 3.9). For the glass rods dose assessment, one sheet of GAFCHROMIC® EBT2 film was 
sandwiched between two slabs of Solid Water®, and the rod was placed on top of the junction of 
the two slabs perpendicular to the surface (Figure 3.10). 
	  
Figure 3.10 View of the glass rods placed on top of the junction of the Gammex Solid Water® 
slabs. EBT2 film was placed between the slabs and on top of the phantom to measure and the 
axial dose profile. 
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To access the dose perpendicular to the axis, a glass rod was placed on top of a 
GAFCHROMIC® EBT2 film. The objective was to experimentally access dose distributions 
within the phantom and on the phantom surface due to a single rod in air and to compare it with 
the MCNPX2.6 simulations of dose distributions within the eyeball. The dose distribution was 
then measured along the axis parallel to the glass rod in the region within the plastic phantom. 
The irradiation time for the glass rod was the same used for the 142Pr solution (2.65 days). In both 
measurement, a small paper funnel guide was used to efficiently placing rods in this positions, 
while decreasing exposure time during measurements. 
3.4 Radiation Safety and Shielding of the Experimental Design 
The safety was considered a priority in performing these experiments. The radiation 
doses were kept as low as reasonably achievable (ALARA) with the help of the East Carolina 
University Radiation Safety Department.  
Dry Box for Handling the Radioactive Material 
An acrylic dry box was used to safely carry out the experiments with 142Pr glass (Fig 
3.11). The 5.5 mm thick acrylic blocked a considerable amount of the beta radiation. Exposure 
levels were measured during the experiment inside and outside the acrylic box and are reported 
in Table 3.1. An additional small acrylic shield was used to place the vial inside the acrylic dry 
box. This shield isolates the samples from the external environment and prevents dispersion of 
the microspheres through the air. The front pannel has two holes placed on the edges for the 
handling the sample. Long tweezers, long wrenches and a double layer of rubber gloves were 
used to manipulate the radioactive samples through the access holes. An access door to the dry 
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box (Fig 3.11, left side) was used to place the solid water phantom and all the tools needed 
before to start the experiment. 
 
 
Figure 3.11: Dry box, water phantoms, shield, long pliers and micropipettes used to carry the 
142Pr measurements. 
Handling the Microspheres Solution 
A syringe shield (Figure 3.12) was used for handling and distributing the radioactive 
solution. The Beta Syringe Shield® reduces hand exposure from syringes containing Strontium-
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89, Phosphorus-32, and other beta-emitting radiopharmaceuticals. The barrel of the syringe 
shield is constructed of 0.375 inches clear plastic with a 0.062 inches thick embedded lead lining, 
which attenuates beta emission and some bremsstrahlung photons. The lead lining is interrupted 
at the viewing window for clear visibility when drawing and administering the dose. A 
thumbscrew holds syringes firmly in place. In the current experiment, a syringe with a long 
needle was used to manipulate the radioactive microspheres solution. 
 
	  
Figure 3.12 Beta syringe Shield 
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All the measurements were performed inside the dry box and plastic gloves were used to 
avoid contamination. Exposure measurements were performed to verify the shielding and safety 
of the experimental procedure. The sample manipulation lasted a total of 10 minutes. Right and 
left hand ring badge and total body badge were using during the experiments. Measurements 
with a portable ion chamber (Eberline RO-20, Thermo Instrument Systems Inc.) registered the 
values described in Table 3.1, prior to the sample manipulation.  
Table 2.1: Measured exposure rates 
Location Detector window Exposure 
10 cm from microspheres Open 15,000 mrem/h 
10 cm from microspheres Closed 37 mrem/h 
Outside Acrylic Box (top) Open 4 mrem/h 
Outside Acrylic Box (top) Closed 3 mrem/h 
Right Hand Aperture Open 10 mrem/h 
Left Hand Aperture Open 80 mrem/h 
Front Part of the Shield Open 8.5 mrem/h 
Front Part of the Shield Closed 2 mrem/h 
Eye Height Open 40 mrem/h 
 
During the entire decay of the nuclide, the samples were located in a controlled room, 
with restricted access to the general public, located in the first floor of the Howell Science 
Complex, at East Carolina University.	   	  
CHAPTER 4: RESULTS 
4.1 142Pr MICROSPHERE BRACHYTHERAPY 
4.1.1 Biological Effective Dose for 142Pr and 90Y 
The calculated values for BED for both 142Pr and 90Y are listed in Table 4.1. An α/β value 
of 10 Gy (tumoral liver), and a total physical dose (PD) of 150 Gy was used for both 
radionuclides. For example, for the lowest DT value considered (17 days), corresponding to the 
fastest growing tumor reported in the clinical literature, the BED calculated for 90Y was 104.9 
Gy, while the BED calculated for 142Pr was 260.0 Gy, representing an increase of 147 %. For the 
highest DT recorded, 720 days, calculated BED for 90Y was 192.3 Gy and for 142Pr it was 299.6 
Gy, representing a 56.3 % increase in the BED. According to the calculated values of BED, the 
difference among radionuclides increases as the doubling time decreases, with the difference 
being more significant for rapid growing tumors. For the healthy tissue, the calculated BED for a 
total physical dose of 10 Gy was 12.0 Gy for 142Pr and 9.02 Gy for 90Y. The comparison of BEDs 
for tumor and normal tissue in liver with physical dose are shown in Figure 4.1.   
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Table 4.1: Calculated BED values for 150 Gy physical total doses for both 142Pr and 90Y. BED 
calculated for the three ranges of tumor growth or Doubling Times (DT) for the different types of 
HCC. The distribution of DT values for each tumor type is positively skewed, therefore, ranges 
of values were considered for BED calculation, instead of a mean value. DT ranges for each 
tumor type were: well differentiated (38-720 days), moderately differentiated (17-380 days) and 
poorly differentiated HCCs (20-70 days) (41). It is observed that the difference for BED values is 
more pronounced for rapid growing tumors. 
Tumor Type Well differentiated Moderately differentiated Poorly differentiated 
DT (days) 38 720 17 380 20 70 
BED (Gy) 90Y 143.4 192.3 104.9 188.5 114.0 162.8 
BED (Gy) 
142Pr 
279.1 299.6 260.0 298.1 264.8 287.7 
% Change 95.1% 56.3% 148% 58.1% 132% 76.7% 
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Figure 4.1 Biological Effective Dose for tumor and non-tumor tissues.  
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4.1.2 MCNPX2.6 Monte Carlo Simulations 
Plots of the calculated DPK for 1 MBq 142Pr and 90Y point sources are shown in 
Figure 4.2. DPK calculation results for 90Y were also compared with results available in the 
literature and benchmarked with the experimental data (Berger, 1971). The default units for dose 
deposition in MCNPX2.6 outputs are MeV/g per decay. Therefore the following conversion 
factor was used to convert the units to Gy per decay: 
1  MeVg = 1.6022  ×10!!"J10!!Kg = 1.6022  ×10!!"Gy Eq. 4.1 
DPK calculations of dose versus distance for 90Y were in close agreement with Berger 
values for all relevant distances considered in this work. The dose rates obtained using 
MCNPX2.6 and BRAIN-DOSE were 0.120 mGy/h and 0.119 mGy/h respectively, at 0.5 cm 
away from the source. Dose distributions from BRAIN-DOSE and MCNPX2.6 codes for a 
1 MBq 142Pr point source are displayed in Figure 4.3.   
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Figure 4.2 DPK calculations for 90Y and 142Pr and comparison with the benchmarked Berger's 
point source calculations for 90Y.  
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Figure 4.3 DPK calculations and MCNPX simulation of the dose distribution for 142Pr. A good 
agreement is observed among both methods.  
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The calculated dose using BRAIN-DOSE code was 4.26% higher than that of 
MCNPX2.6 code for this distance. MCNPX2.6 provided the dose per particle for both beta and 
gamma contributions for 142Pr and beta contribution for 90Y. For distances beyond 0.6 cm 
MCNPX2.6 presented a higher dose rate than the one observed for BRAIN-DOSE calculations. 
The differences between these results are due to the fact that MCNPX2.6 accounts for radiation 
backscatter and electron multiple interactions, as described by the continuous-slowing-down 
model. These considerations will increase the dose rate, especially for low energy electrons. 
BRAIN-DOSE uses the convolution method to calculate the dose, which does not account for 
energy straggling radiation (Mainegra-Hing et al., 2005), therefore yielding a lower dose for 
points away from the source. Even though the differences are large for points beyond 0.6 cm, the 
dose relative to the total dose for these points is low compared to the prescription dose, e.g. at 0.8 
cm, MCNPX2.6 calculates 0.0139 cGy/hr and BRAIN-DOSE gives 0.0004 cG/hr, representing 
less than 0.05% of the dose rate at points close to the source.  
The MCNPX2.6 simulation of the beta dose distributions for 142Pr microspheres within a 
2.5 cm tumor are shown in the Figure 4.4. Comparison of the total physical dose along the 
central axis due to gamma and beta contributions for 142Pr and total physical dose due to beta 
contribution for 90Y are displayed in Figure 4.5. For these results, a target dose of 150 Gy within 
the tumor was used for both nuclides. From the simulation, a beta and gamma dose per decay of 
1.95 × 10-12 Gy and 9.77 × 10-15 Gy, respectively, were obtained for 142Pr inside the tumor. A 
beta dose per decay of 2.36 × 10-12 Gy was obtained for 90Y at the same point. To obtain the 
desired total physical dose at the center, a total initial activity of 0.662 GBq and 0.191 GBq was 
calculated for 142Pr and 90Y, respectively. The beta contribution to the dose drops quickly to zero 
for points outside the tumor, in this case for points greater than 2.5 cm.   
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Figure 4.4 Contour plot of the MCNPX2.6 simulation of dose (Gy) distribution for 142Pr 
microspheres in a 2.5 cm spherical tumor model (dose at the central plane of the tumor). The 
target physical dose was 150 Gy. The dose drops quickly to zero for regions outside the tumor, 
delivering a high dose inside the tumor and sparing the surrounding healthy tissues. Fluctuations 
observed on the top surface are due to statistical uncertainties intrinsic of the Monte Carlo 
method.  
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Figure 4.5 Central axis view of the beta and gamma contributions to the dose due to 142Pr and 
beta contribution due to 90Y. Gamma contribution to the total dose for 142Pr cannot be 
distinguished in the plot, since it is about 100 times smaller than the beta dose at the origin. 
Doses due to 90Y are due to beta only and decay quickly to zero.  
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Different sizes of spherical tumors were also considered to determine dose distributions 
inside the tumor and in the tumor surroundings. Dose per disintegration for tumor radii of 1.0, 
2.0, 2.5, 3.0, 4.0 and 5.0 cm are displayed in Figure 4.6. Total dose distributions due to the 
gamma contributions (during entire life of the nuclide) were obtained for a 1.0 cm sphere and 
compared with results obtained by MCNPX2.6 simulation (Figure 4.7). A 9 GBq vial of 142Pr 
homogeneously distributed within a 1 cm radius tumor was used. Overall, a good agreement was 
observed between MCNPX2.6 simulation and analytical calculations, with total dose within 1% 
for points at the tumor center.  
The dose distribution within the tumor for blood vessels completely filled with 142Pr and 
90Y are shown in Figure 4.8. The total physical dose distributions near the modeled blood vessels 
both inside the tumor and at the tumor periphery completely filled with 142Pr are shown in 
Figure 4.9. The total dose was calculated considering the total decays from the entire treatment 
period of 120 microspheres, or 1.0 × 1011 decays. 
Based on the simulated physical dose distribution, the BEDVH distributions both 90Y and 
142Pr was calculated for 150 Gy (Figure 4.10). The summary of these findings for all the tumor 
vessels and tumor sizes studied are listed in Table 4.2 for tumor DT of 20 days. The ambient 
dose rates due to the 142Pr gamma component calculated for a vial containing 1.2 × 106 
microspheres (10.1 GBq) of 142Pr was 0.081 mSv/hr. For this vial size and the entire life of this 
nuclide the total exposure is calculated to be 2.24 mSv. This calculation was based on 
conservative assumption that the attenuation from body was not accounted for and the family or 
caregivers stayed with the patient at 1 meter during entire treatment period. 
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Figure 4.6 Tumor radiuses ranging from 1 cm to 5 cm. Comparable dose decay curves along the 
central axis per beta decay for 142Pr (filled symbols) and 90Y (unfilled symbols).  
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Figure 4.7 Validation of the MCNPX simulations for the 142Pr gamma dose distribution using 
the analytical calculations. Mathematica software was used to perform the volume integrals 
throughout the tumor. Initial activity of 9 GBq homogeneously distributed within a 1 cm radius 
tumor.  
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Figure 4.8 Simulation of the dose distribution (Gy) generated by the 20 µm diameter blood 
vessel model (white line in the center) within a 0.5 cm tumor.  
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Figure 4.9: Dose distributions for a blood vessel placed in the center of tumor and placed at the 
tumor boundary.  
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Figure 4.10: Biological effective dose volume histogram.   
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Table 4.2: Percent of the tumor volume covered with a BED higher than 150 Gy for different 
tumor radius and blood vessel diameters for both 142Pr and 90Y for a 20 days doubling time. 
 Blood Vessel diameter* 
 25.0 µm 50.0 µm 75.0 µm 
Tumor Radius 142Pr 90Y 142Pr 90Y 142Pr 90Y 
0.2 cm 89.2 60.0 100 100 100 100 
0.5 cm 19.9 11.9 40.2 28.6 57.8 44.0 
1.0 cm 5.77 4.93 10.7 11.1 15.7 14.0 
* Diameters were based on average hepatic blood vessel diameter sizes reported in the literature 
(Kennedy et al., 2004)  
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4.1.3 MCNPX2.6 Model for 142Pr glass microsphere experimental design 
MCNPX2.6 outputs for the modeled experimental setup are displayed in Figure 4.11. The 
filled contour plots represent both xy and yz-axis dose distributions per decay. After multiplied 
by the total number of decays, the total dose profiles are compared in the next section with the 
experimental measurements. In addition, a linear profile (Figure 4.12) is plotted with more 
detailed information of dose (Gy) per decay as a function of the distance from the glass capillary.   
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Figure 4.11: Dose (Gy) distributions per decay for a glass capillary filled with glass 142Pr 
microspheres, having internal diameter of 305 µm and external diameter equals to 457 µm.  
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Figure 4.12: Linear-log plot of the dose distributions (Gy) per decay for a glass capillary filled 
with glass 142Pr microspheres, having internal diameter of 305 µm and external diameter equals 
to 457 µm.  
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4.2 142Pr CONFORMAL EYE BRACHYTHERAPY DEVICE 
Results obtained for the simulations for dose within the eyeball for a glass 142Pr rods and 
total dose of 85 Gy will be presented. Comparison of dose per decay for a total dose equal to 
85 Gy for 142Pr, 90Y and 188Re sources will also be presented and discussed in the following 
sections. 
4.2.1 MCNPX2.6 142Pr Dose distribution within the eye 
The beta dose profile found within the eyeball due to the glass 142Pr rod (Figure 4.13) 
shows that this nuclide provides a short-range dose profile suitable for the treatment of 
superficial eye lesions. The dose at the eye surface was calculated as 85.0 Gy and 2.95 Gy at 
5.00 mm with an error of less than 1% (i.e. 0.139 and 0.855% respectively). Figure 4.14 shows 
the log-log plot of the axial dose profile versus depth. 
4.2.2 Comparison of 142Pr, 90Y and 188Re dose distributions 
The simulated dose per decay at 1 mm from the eye surface at the central axis for 142Pr, 
90Y, and 188Re, were 4.16 × 10-11, 6.57 × 10-11, and 3.85 × 10-11Gy respectively. The log-log plots 
of the dose per decay and total dose curves for all the nuclides studied are shown in Figure 4.15. 
For an 85 Gy total dose at the eye surface, the observed dose at 1 mm for 142Pr, 90Y, and 188Re 
were 52.1, 55.3, and 50.5 Gy, respectively. Activation of 142Pr and 188Re can be achieved in low 
fluence neutron research reactor, making these nuclides more accessible and lowering production 
costs. For all nuclides studied, the beta dose profile showed that this device might provide very 
high doses at short ranges within the eyeball, suitable for the treatment of superficial eye lesions. 
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The radionuclide 90Y showed the highest dose per decay at the point studied, 70.6 % higher than 
188Re and 57.9% higher than 142Pr. Dose penetration for 90Y was also higher than 188Re (9.5%) 
and 142Pr (6.1%).  
Glass 142Pr CEBT device is a promising technique for the treatment of superficial eye 
cancers. One of the advantages of the 142Pr eye device is that it could be positioned for any 
particular desired dose distribution, according to the tumor shape and size. Monte Carlo 
simulation allows determination of the dose distribution for different configurations and 
sequences. 
4.2.3 MCNPX2.6 model for experimental design of one 142Pr glass rod 
Simulated dose distribution within a squared water phantom using one rod is displayed in 
Figure 4.16. The first profile is the axial dose distribution of electrons within the water phantom. 
The second dose profile is the radial dose distribution at the water-air interface on top of the 
phantom. A mesh tally of 30 × 30 × 30 and having 1 cm3 was used in this simulation. A log-log 
plot of the radial profile of the dose distribution due to one rod in water is displayed in 
Figure 4.17.  
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Figure 4.13 Dose (Gy) distribution inside the eye for a 142Pr rod. A total dose 85 Gy was 
delivered at 0.01 cm from the eye surface. 
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Figure 4.14: Axial profile of dose (Gy) per decay due to one 142Pr rod touching the eye surface. 
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Figure 4.15: Comparison of dose profiles for 142Pr, 90Y and 188Re. First plot shows dose per 
decay and second plot shows the dose distribution for 85 Gy dose at the surface.  
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Figure 4.16: MCNPX2.6 transversal and radial simulations for the dose (Gy) per decay profile 
of model used for experimental setup.  
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Figure 4.17: Axial profile of dose (Gy) per decay due to one 142Pr rod in contact with a squared 
water phantom. 
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4.3 Experimental Results and Monte Carlo Validation 
Figure 4.18 shows the 142Pr spectrum measured with the NaI scintillator detector for 30 
minutes. A 1578.2 keV peak was observed due to 142Pr gamma yield. Film measurements for 
142Pr glass microsphere and rod are presented and compared with simulated dose profile.  
4.3.1 142Pr glass microspheres 
Figure 4.19 shows the GAFCHROMIC® EBT2 film measurement for the glass capillary. 
Some dark spots are observed in the film, due to lose microspheres that were around the glass 
capillary before it was released in the water. The horizontal lines in the bottom are from 
imperfections in the scanner surface. The top part of the dose profile is wider than the bottom 
part, indicating a difference in microsphere concentration within the capillary. Figure 4.20 shows 
the isodose lines plotted in ImageJ. To plot the isodose lines, the image was split into RGB 
channels, and rec component was converted into a 16-bit gray scale. Gray scale was calibrated 
using the gray value and corresponding film dose from the calibration in electron beam.  
In order to compare the simulation results with the experimental data, the dose per decay 
was multiplied by the total decays. The final length of the capillary was 32.0 mm and it had 
internal diameter was 305 µm. Considering that the average diameter of the microspheres was 
29.7 µm and the microsphere solution having 30.8 ×106 microspheres per ml, a total number of 
70,086 microspheres were estimated within the capillary. The total activity delivered at the time 
of experiment was 36.6 mCi (1.35 × 109 Bq) for a total of 3.08 × 106 microspheres in a 0.169 g 
sample. Therefore, each microsphere had 440 Bq at the time of the measurements. The film was 
irradiated for 51 hours, therefore, the whole sample went through a total of 2.6 × 1012 decays. 
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Figure 4.21 shows the isodose lines for the MCNPX2.6 total dose simulations. The 
comparison for MCNPX2.6 simulations with film dosimetry are shown in Figure 4.22 for the 
glass microspheres. Measurements and simulations agree within 3.9 % for doses below 
1600 cGy, e.g. experimental and simulated doses obtained at 0.5 cm from the source were 
1547 cGy and 1610 cGy respectively. For doses of 1650 cGy and above, the sensitivity of the 
film is a limiting factor for accurately detecting doses. Therefore, a discrepancy is observed for 
this areas.  
4.3.2 142Pr glass rods 
Film measurements for an axial and transversal axis of the rods on top of a water 
phantom are presented in Figure 4.23. The isodose lines in cGy were plotted in ImageJ in the 
16-bit red channel (Figure 4.24). To calculate the total number of decays, the total activity of the 
sample was divided by ten, which was the number of rods in the sample. Each rod had 
approximately 7.63 mCi (0.282 GBq), and stayed in the solid water phantom for 51 hours. A 
total number of decays of 2.36 × 1013 decays were calculated for 51 hours of decay. In Figure 
4.25 the simulated dose profile (cGy) for the total number of decays is presented. 
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Figure 4.18: 142Pr Spectrum measured with the NaI scintillator detector. The peak observed is at 
the energy 1578.2 keV, corresponding to 142Pr gamma energy. 
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Figure 4.19: Raw scan of GAFCHROMIC® EBT2 film measurement for the glass capillary 
filled with 142Pr microspheres. The small dark spots in the film are due to lose microspheres 
outside the capillary during pipetting.  These microspheres dispersed in the water and deposited 
on the bottom of the phantom.  
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Figure 4.20: Isodose lines (cGy) for the glass microcapillary dose measurements in 
GAFCHROMIC® EBT2 film (red channel converted to a 16-bit image).  
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Figure 4.21: Monte Carlo Simulation (cGy) for a total of 70,000 142Pr glass microspheres in a 
glass capillary.  
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Figure 4.22: Monte Carlo and GAFCHROMIC® EBT2 film measurements for the 142Pr glass 
microspheres. Discrepancies for higher doses in MCNPX2.6 when compared to the 
measurements are due to the lack of film sensitivity in the red channel (above 1000 cGy).  
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Figure 4.23: Axial and transversal GAFCHROMIC® EBT2 film measurement of 142Pr glass rod.   
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Figure 4.24: Isodose lines (cGy) for the glass rods dose measurements in GAFCHROMIC® 
EBT2 film (red channel converted to a 16-bit image).  
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Figure 4.25: Monte Carlo Simulation (cGy) for a total of decays of a 142Pr glass rod   
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4.4 Monte Carlo and Experimental Uncertainties Considerations 
The number of histories used in MCNPX2.6 Monte Carlo simulations was great enough 
to guarantee less than 1.5% uncertainty associated with the energy deposition. Number of 
histories varied from 1 × 105 to 1 × 107, depending on the distances considered and particle used 
(photons or electrons). For the measurements of dose deposited in film, uncertainties regarding 
the activity, time, and sample positioning were analyzed. For the sample activity values, 
uncertainties related to the sample total mass, irradiated time and shipping time were estimated 
in ± 5%, ± 1% and ± 6% respectively. For the sample handling and placement in the phantom, it 
was estimated an uncertainty of ± 1%. During the measurements the glass capillary inside the 
water phantom remained in place. However, displacements were observed in the position of the 
rods that were in air in relation to the film positioning. These variations in positioning were 
estimated as being ± 5%. Considering that the dose deposited in the film were a function of total 
time, initial activity and sample positioning, the sensitivity analysis of the dose is given by: 
𝛿𝐷𝐷 = 𝐷 𝑡 + 𝛿𝑡 , 𝑎 + 𝛿𝑎 , 𝑝 + 𝛿𝑝 − 𝐷[𝑡,𝑎,𝑝]𝐷[𝑡,𝑎,𝑝]  Eq. 4.1 
where D is the dose, t is the time, a is the activity and p is the position and their respective 
uncertainties are represented by the delta. Estimated uncertainty in the dose was calculated as 
being ± 11%.   
CHAPTER 5: DISCUSSIONS & CONCLUSIONS 
In this work, a dosimetric study for microsphere brachytherapy and conformal eye 
brachytherapy device was performed. Praseodymium-142 glass microspheres and glass rods 
were activated and dose measurements were performed using GAFCHROMIC® EBT2 film. A 
realistic dose distribution of microspheres in a single blood vessel was modeled and experiments 
were performed using a glass micro capillary filled with 142Pr glass microspheres solution. Dose 
to different distances from the source as well as external exposures were calculated. Experiments 
were performed with 142Pr microspheres using radiochromic film in a Solid Water® plastic 
phantom to validate the simulations. A more realistic dose distribution of microspheres in a 
single blood vessel was investigated. Measurements with activated 142Pr microspheres in a glass 
microcapillary using EBT2® radiochromic film was performed and compared with the simulated 
dose. This work presented a detailed dosimetric study of 142Pr microsphere, providing both 
simulation and experimental validation for the simulations, as well as biological effective dose 
calculations. It was shown that 142Pr is a possible choice of radionuclide for treating 
Hepatocellular Carcinoma. This opens possibilities for animal studies by further research groups 
or private companies interested in manufacturing 142Pr glass microspheres as well as performing 
clinical trials. For the CEBT device, 142Pr glass rods showed to be a good candidate for 
applications in HDR eye brachytherapy, delivering highly target doses to the eye surface 
restricted to shallow depths. This opens possibilities of applications of this device in other 
superficial malignancies, such as skin cancer. 
The activation of 142Pr can be achieved in a low neutron fluence reactor. Some concern 
could be raised, regarding radioactive contamination due to the other components besides the 
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142Pr. During the neutron activation process, three of the 142Pr REAS glass components (Si and 
Al, and Pr) are activated in the reactor. However, 28Al has only 2.24 min half-life, 31Si has 2.62 h 
half-life with a small yield of gamma rays (0.07%), and the production of 143Pr with 13.57 d half-
life is negligibly small during activation (1.2 × 10-6). Energy spectrum of activated 142Pr glass 
samples was measured, confirming that impurities are not a concern in the activation of this 
nuclide. 
5.1 142Pr Microsphere Brachytherapy 
Microsphere brachytherapy for the treatment of hepatic malignancies using 142Pr is an 
alternative possibility in addition to the current used radionuclide 90Y, especially for rapid 
growing tumors with high doubling times. 142Pr microspheres can be easily activated in a low 
neutron flux reactor such as 1 Megawatt TRIGA (Training, Research, Isotopes, and General 
Atomics) reactor or may be activated in larger research reactors such as the 10 MW MURR®. 
These reactors are found in several research centers, making it widely available and possibly 
reducing total treatment costs for microsphere brachytherapy of the liver due to the proximity of 
the activation to the treatment site. Gamma emitting impurities generated during the activation 
process are expected to be negligible and therefore are not of concern regarding additional dose 
to the patient and staff. However, precaution should be taken during production of microspheres 
to avoid additional impurities. The gamma component of 142Pr would potentially allow a direct 
verification of the sample activity, using NaI detector, as well as excellent control of possible 
contaminations, by using a survey meter. 
The time to deliver 90% of the dose (T90) for 142Pr is approximately 30% of T90 for 90Y. 
This is one advantage of using 142Pr over 90Y, since the longer the time to deliver the dose, the 
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higher is the risk of dose to healthy tissue due to migration to adjacent organs (especially to 
lungs)  (Kennedy et al., 2007). A second advantage is that shorter half-lives are preferred due to 
the higher BED to the HCC. Considering and the additional dose to normal tissues, 142Pr 
microspheres would be more beneficial to the patients with less expected shunting from 
pretreatment 99mTc scan. 
Physical dose distributions and penetration ranges due to 142Pr were comparable to the 
ones of the currently used radionuclide 90Y. Point sources, as well as an ensemble of 
microspheres, were analyzed and point source data could be used to access the physical dose 
delivered to the patient. Ambient dose rates and total dose per a vial were calculated for 142Pr 
gamma component in order to estimate the radiation safety risks presented by this nuclide. 
Ambient dose rates and total dose were found to be 0.081 mSv/hr and 2.24 mSv, respectively 
which are below the exposure limits at one meter from the source. Based on the 10 CFR 35 (U.S. 
Nuclear Regulatory Commission, 2007), occupational exposure (50 mSv) and exposure of public 
limits (5 mSv if infrequent) per year should be observed. Radiation levels to the public and staff 
should be kept as low as reasonably achievable (ALARA). Therefore additional precaution may 
be necessary, such as avoiding proximity with the patient by the caregivers and family within the 
first few days after treatment.  
The models used in the study of 142Pr were based in uniform distribution of activity inside 
tumors and blood vessels. The blood vessel located at the tumor periphery is a more realistic 
model for the microsphere distribution in the liver, but still considers a uniform distribution of 
radioactivity. Other uniform distribution studies have been proposed in the literature for 90Y dose 
distribution, e.g. partition models, in which the tumor and liver are subdivided into small voxels, 
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containing uniform activities (Ho et al., 1996). In addition, models using uniform distribution of 
activities have been used in imaging studies in an attempt to improve the assessment of the dose 
delivered to the patient (Rong et al., 2012). Tumor and liver sizes and shapes can vary 
significantly from one patient to another (Sarfaraz et al., 2004). For a more detailed dose 
distribution in a particular patient, a CT scan of the patient would be necessary, followed by a 
SPECT-CT image after dose administration to measure the actual bremsstrahlung distribution. 
Uniform distribution within voxels for patient specific dose determination was successfully used 
by Sarfaraz et al. (2004) to describe the dose distribution in the tumor and adjacent organs, such 
as the kidneys and stomach. The reverse technique, using the 142Pr dose distribution for a point 
source or a voxel, can be used for treatment planning purposes. This opens possibilities for a 
future route of this work, possibly starting phantom measurements and animal trials prior to 
future clinical trial. 
Blood vessels uniformly filled with 142Pr and 90Y microspheres were modeled and 
simulated using a Monte Carlo code. Analysis of the dose distribution due to a single embolized 
blood vessel leads to a more realistic estimation of how microspheres are deposited in the tumor. 
Characterization of high physical and biological effective doses constrained to short distances, 
such as obtained from a single blood vessel, may be useful to the current studies being performed 
on the bystander effect, observed for highly localized doses (Dewhirst et at., 2012). 
Post treatment biodistribution of the 90Y glass microspheres and dose distribution has 
been assessed through the detection of Bremsstrahlung photons produced by the beta particles 
(Rault et al., 2010; Poorbaygi et al., 2011) and scarce signal from positron emission (Gates et al., 
2010). The low energy bremsstrahlung photons are highly scattered in the tissue, leading to a 
	   112	  
poor spatial resolution of the dose distribution due to the very low signal (Rong et al., 2012). One 
of the issues with using SPECT for measurement of bremsstrahlung from 90Y is determining 
directionality (Rahmim and Zaidi, 2008), which can be improved with the use of pinhole 
cameras.  The range of travel in PET is a limiting factor in the spatial resolution. In the attempt 
to improve resolution, PET has been proposed in conjunction with CT imaging for the 
optimization of 90Y processing (Hsiang et al., 2011). Recently the administration of a gamma 
emitter (e.g. Lutetium-177) concurrent with 90Y has been proposed to overcome issues related to 
the imaging resolution (Poorbaygi et al., 2011). The intrinsic gamma yield of 142Pr allows for 
potential post treatment imaging (Pelletier and Jung, 2012). Low dose rate mono-energetic 
photon could be detected using conventional detectors (i.e. NaI scintillation detector) for activity 
verification before treatment, while delivering a very low dose to the patient. 142Pr could be 
imaged with 1.58 MeV gamma photons. As the photon signal is strong enough from this isotope, 
Xenon detectors could be used to image the microspheres (Keller et al., 2002). Using good 
filtration and septa to reduce the inter-detector noise, the 1.58 MeV photon would allow for 
accurate imaging of the microspheres, with the additional benefit of the strong signal relative to 
142Pr after passing through the body. The detection of high-energy gamma detection is still 
challenging because of more Compton scattering and needs further investigation. 
5.1.1 Future work 
Future work in 142Pr microsphere brachytherapy includes the study of imaging techniques to 
detect microspheres post treatment and assessment of the dose delivered. Also important is the 
study and development of a standardized technique to measure the vial activities using gamma 
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detectors. Animal studies may be done prior to the implementation of 142Pr glass microspheres 
for clinical purposes. 
5.2 Conformal Eye Brachytherapy Device 
This work purposed a preliminary dosimetric study of glass 142Pr and its possible 
applications in eye brachytherapy. Furthermore, it was intended to propose a novel design to the 
current eye plaque brachytherapy, capable of greater dose conformality in the tumor. However, 
further studies have to be done on the conformal eye brachytherapy (CEBT) device. The future 
steps will be followed by a patent application. 
The conformal eye brachytherapy (CEBT) device would allow for the treatment of a 
tumor based on its shape and depth, providing a more conformal dose to the target. The 
preliminary simulation studies using the beta emitter 142Pr showed a short penetration depth and 
strong localization of the dose deposited to shallow regions, making this device suitable for 
treating superficial lesions, while sparing healthy tissues. This is proposed specifically for eye 
tumors, however, based on its geometry and physical properties, its use may be suitable for 
treating other types of superficial tumor, such as melanomas and squamous cell carcinomas. 
Glass eye plaque using Re-188, Pr-142, and Y-90 are viable for the treatment of 
superficial eye cancers, due to the high doses achieved in short distances, sparing healthy 
surrounding issues. Glass eye plaques could also be further molded according to the tumor shape 
and size to achieve the desired dose distribution. The feasibility and costs of each of these 
radionuclides should be taken into account for each clinical setup configuration, time from the 
nuclide activation to dose delivery, and desired dose penetration in tissue. 
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5.2.1 Patent application and Future Work 
This research project proposes to develop a novel conformal brachytherapy device using 
the beta- minus emitters to treat superficial human eye tumors and malignancies.. The proposed 
technique is especially designed to benefit numerous patients suffering from eye cancer in the 
US and in the world. In the future, this innovative device may have its use extended to treat other 
forms of superficial cancer, e.g. melanomas, basal and squamous cell carcinoma and body parts 
of difficult access as mentioned before. 
It is intended to fully design and finalize the patent for the 142Pr CEBT device prior to 
seeking a scientific partnership for physically developing the conformal eye brachytherapy 
design. Costs may be elevated, especially for the initial price of fully developing this device. It is 
intended to: (1) fabricate the 142Pr CEBT device, having a digital remote controller and shielding 
case, (2) develop a software to calculate the rods positioning and temporal sequence to produce 
the desired dose, (3) to design a solid water phantom to simulate the eyeball, (4) to measure dose 
delivered using a NaI array detectors, (5) to perform animal tests prior to the clinical 
implementation of the device. 
For the 142Pr CEBT device, customized rare earth aluminum silicate (REAS) glass rods of 
cylindrical geometry with flat ends may be custom ordered from the manufacturer. A digital 
controlling system would allow manipulating the device and radioactive rods from the outside of 
the treatment room, minimizing dose to the staff. A patent application is in process and in the 
future, collaboration with private companies will allow developing an accurate digital controller. 
A Plexiglas shield, for handling the device, can be used and radial and depth dose measurement 
can be done using RADIOCHROMIC® film. It is intended to perform future animal tests or 
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clinic tests of the novel CEBT device developed in this research. 
Planning and delivering the planned dose 
A planning system to customize the radiation fields for a given tumor may be developed 
for the CEBT device. The planning of dose delivered can be done based on the tumor geometry 
and prescribed dose. Ultrasound imaging of the tumor (Char et el., 2002) may be used to access 
the depth and tumor extent within the eyeball. Dose delivery and rod positioning may be guided 
in real time by using a high-resolution medical camera. After total dose is prescribed and the 
planning target volume (PTV) contoured the treatment fields will be optimized using computer 
software. For the treatment delivery, patient specific quality assurance should be performed, and 
total planned dose should be verified prior to the actual treatment. After verification and proper 
consideration of the radionuclide decay, the applicator is positioned and the planned treatment 
can be delivered. 
Quality Assurance Methods Proposed for the CEBT 
Development of a quality assurance method for verification of the device and planning is 
necessary to ensure that the correct dose is delivered to the site. Due to the size of the device and 
the fact that 142Pr presents a 3.7% gamma yield, the most appropriate method for quality 
assurance (QA) would be an array of HPGe or NaI detectors. This array could be made with the 
same number of detectors as rods in the treatment device, allowing the required spatial 
resolution. Computer based program will generate the corresponding 2D dose distribution to be 
compared with measurements. Well- established methods such as the distance to agreement 
(DTA) could be used to verify the passing rate of the fields delivered.   
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APPENDIX A: MCNPX2.6 INPUTS 
 
 
A.1: Microsphere Brachytherapy Inputs: 
 
A.1.1: Source homogeneously distributed model for spherical tumor 
 
 
Beta dose at water due to homogeneously distributed microspheres within a 5.0 cm tumor 
c Cell Cards 
c Pr source 
5  3 -1.0   -2      imp:p,e=1  
c   
900 3 -1.000 -6  #5  
                 imp:p,e=4  
c void 
999 0  6   imp:p,e=0 
c end of cell cards 
c surface card 
c surface of water 
c radius of microsphere (10.0 cm diameter) 
2  SO  5.0 
6  SO  12.0 
c end of surface cards 
MODE p e  
c material card 
c Si:Al:Pr:O (weight percent) 
m1 14000 -0.153  13000 -0.081  59000 -0.445  8000 -0.322 
c water 
c   H : 2   O : 1 
m3 001001 2 008016 1  
SDEF cell=5 ERG=d1 rad=d2 PAR=3   
SI1 A 0.017 0.172 0.265 0.395 0.574 0.766 0.877 0.946 1.026 1.188  
       1.268 1.343 1.615 1.712 1.884 1.923 2.011 2.064 2.104 2.139 2.160  
SP1 D 586 656 673 669 649 632 613 598 578 527  
       497 464 311 244 121 95.2 43.4 19.8 7.32 1.19 0.0069  
SI2 0 5.0 
SP2 -21 2 
c  E0 
c  F8:P 10 
c mesh tally 
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tmesh 
c  xz plane 
   rmesh1:e pedep 
   cora1  0.0  19i  6.0 
   corb1  -0.30  0.30 
   corc1  -0.30  0.30 
endmd 
NPS 2.0E6 
PRDMP 1E7 1E8 0 4 
DBCN 18J 1  $ITS-style energy indexing 
PRINT 
c PRINT -10 -40 -50 -70 -98 -85 -86 -110 -140 -170 -130 -128 
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A.1.2: Cylindrical blood vessel model 
 
 
 
Beta dose at water  
c BLOCK 1 
c***********************************CellCards*********************************
******* 
c 
5   1 -4.0   -3 -2       imp:p,e=1  $142-Pr source (cylindrical blood vessel inside tumor) 
c 5   1 -3.29  -3 -2     imp:p,e=1  $90-Y source (cylindrical blood vessel inside tumor) 
100 3 -1.000 -2  #5      imp:p,e=1  $Tumor (water, R=0.5, 1.0, and 1.5 cm) 
900 3 -1.000 -6  #5 #100 imp:p,e=4  $Outside medium (water, R=12.0cm) 
999 0  6                 imp:p,e=0  $Void 
c BLOCK 2 
c**********************************SurfaceCards*******************************
******* 
c 
2  SO  0.5                $Surface of tumor (R=0.5, 1.0, and 1.5 cm) 
3  C/Z 0 0 0.0010         $source/arteries (12-30um diameter, aver. r=10e-6m=10e-4cm) 
6  SO  12.0               $Surface of water/medium (12.0 cm radius) 
c BLOCK 3 
c************************************DataCards*******************************
******* 
c  
MODE P E 
c  
c ----------------------------------- Material Card -------------------------------------- 
c  
c                                 ** Pr Glass ** 
c                          Si:Al:Pr:O (weight percent) 
c 
M1 14000 -0.153  13000 -0.081  59000 -0.445  8000 -0.322 
c 
c                                 ** Y Glass ** 
c                             Si:Al:Y:O (weight percent) 
c 
c M1 14000 -0.194 13000 -0.106 39000 -0.303 8000 -0.397  
c 
c                                  ** Water ** 
c                           H:2 O:1 (atomic abundance) 
c  
M3 001001 2 008016 1  
c  
c --------------------------------- Source Definitions ----------------------------------- 
c 
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c          SDEF: Cell 5; Tabulated Energies (A); Radial Distance; Electron; 
c  
SDEF POS 0 0 0 AXS=0 0 1 EXT=d2 RAD=d3 ERG=d1 PAR=3 
c 
c                    ** 142-Praseodymium BETA ENERGY DISTRIBUTION ** 
c 
c          ** use this energy distribution for 142-Praseodymium simulations ** 
c  
SI1 A 0.017 0.172 0.265 0.395 0.574 0.766 0.877 0.946 1.026 1.188  
1.268 1.343 1.615 1.712 1.884 1.923 2.011 2.064 2.104 2.139 2.160 
SP1 D 586 656 673 669 649 632 613 598 578 527  
       497 464 311 244 121 95.2 43.4 19.8 7.32 1.19 0.0069 
c 
c                       **  90-Yttrium BETA ENERGY DISTRIBUTION ** 
c  
c            ** use this energy distribution for 90-Yttrium simulations ** 
c 
c SI1 A 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0  
c        1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1  
c SP1 D 406.1 476.2 528.1 566.1 593.4 612.1 623.7 628.8 627.6 619.9   
c        605.2 582.8 552.3 513.1 465.3 409.2 345.9 277.0 205.3 134.3 69.0 
SI2  -0.5   0.5               $radial sampling range (set as same tumor radius) 
SP2  -21    0                 $uniform sampling for line 
SI3   0     0.0010            $radial sampling range from 0 to Rmax (same as blood vessel) 
SP3  -21    1                 $radial sampling probability 
c  E0 
c  F8:P 10 
c  
c ------------------------------------ Mesh Tally ------------------------------------ 
c  
tmesh 
c  xz plane 
   rmesh1:e pedep 
   cora1  -0.50 29i 0.50 
   corb1  -0.50 29i 0.50 
   corc1  -0.50  9i 0.50 
endmd 
NPS 2.0E7 
PRDMP 1E7 1E8 0 4 
DBCN 18J 1  $ITS-style energy indexing 
PRINT 
c PRINT -10 -40 -50 -70 -98 -85 -86 -110 -140 -170 -130 -128 
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A.1.3 Glass Capillary filled with 142Pr 
 
 
Beta dose at water  
c BLOCK 1 
c ******************************** Cell Cards ******************************** 
c 
5   1 -4.0   -3 -11 12        imp:p,e=1  $142-Pr source (cylindrical blood vessel inside tumor) 
c 5   1 -3.29  -3 -2          imp:p,e=1  $90-Y source (cylindrical blood vessel inside tumor) 
10   4  -2.52  -4 -11 12  #5  imp:p,e=1  $Glass capilary  
c 100 3 -1.000 -2  #5          imp:p,e=1  $Tumor (water, R=0.5, 1.0, and 1.5 cm) 
900 3 -1.000 -6  #5 #10       imp:p,e=4  $Outside medium (water, R=12.0cm) 
999 0  6                      imp:p,e=0  $Void 
c BLOCK 2 
c ****************************** Surface Cards ******************************* 
c 
c 2  SO  0.5               $Surface of tumor (R=0.5, 1.0, and 1.5 cm) 
3  C/Z 0 0 0.0300         $capilary glass internal diameter    
4  C/Z 0 0 0.0450         $capillary glass external diameter 
11 PZ  1.5                $capillary top 
12 PZ -1.5                $capillary bottom  
6  SO  12.0               $Surface of water/medium (12.0 cm radius) 
c BLOCK 3 
c ****************************** Data Cards ********************************** 
c  
MODE P E 
c  
c ----------------------------------- Material Card -------------------------------------- 
c  
c                                 ** Pr Glass ** 
c                          Si:Al:Pr:O (weight percent) 
c 
M1 14000 -0.153  13000 -0.081  59000 -0.445  8000 -0.322 
c 
c 
c                                 ** Y Glass ** 
c                             Si:Al:Y:O (weight percent) 
c 
c M1 14000 -0.194 13000 -0.106 39000 -0.303 8000 -0.397  
c 
c  
c                                  ** Water ** 
c                           H:2 O:1 (atomic abundance) 
c  
M3 001001 2 008016 1  
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c  
c 
c                                  ** Glass (Capillary Walls)** 
c                             Si:Al:Na:Ca:O (weight percent) 
c 
M4 14000 -0.345 13000 -0.0068 11000 -0.0953 20000 -0.075 8000 -0.4779 
c 
c 
c 
c --------------------------------- Source Definitions ----------------------------------- 
c 
c          SDEF: Cell 5; Tabulated Energies (A); Radial Distance; Electron; 
c  
SDEF POS 0 0 0 AXS=0 0 1 EXT=d2 RAD=d3 ERG=d1 PAR=3 
c 
c                    ** 142-Praseodymium BETA ENERGY DISTRIBUTION ** 
c 
c          ** use this energy distribution for 142-Praseodymium simulations ** 
c  
SI1 A 0.017 0.172 0.265 0.395 0.574 0.766 0.877 0.946 1.026 1.188  
       1.268 1.343 1.615 1.712 1.884 1.923 2.011 2.064 2.104 2.139 2.160 
SP1 D 586 656 673 669 649 632 613 598 578 527  
       497 464 311 244 121 95.2 43.4 19.8 7.32 1.19 0.0069 
c 
c                       **  90-Yttrium BETA ENERGY DISTRIBUTION ** 
c  
c            ** use this energy distribution for 90-Yttrium simulations ** 
c 
c SI1 A 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0  
c        1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1  
c SP1 D 406.1 476.2 528.1 566.1 593.4 612.1 623.7 628.8 627.6 619.9   
c        605.2 582.8 552.3 513.1 465.3 409.2 345.9 277.0 205.3 134.3 69.0 
SI2  -2.5   2.5               $radial sampling range (set as same tumor radius) 
SP2  -21    0                 $uniform sampling for line 
SI3   0     0.0300            $radial sampling range from 0 to Rmax (same as blood vessel) 
SP3  -21    1                 $radial sampling probability 
c  E0 
c  F8:P 10 
c  
c ------------------------------------ Mesh Tally ---------------------------------------- 
c  
tmesh 
c  xz plane 
   rmesh1:e pedep 
   cora1  -1.50 29i 1.50 
   corb1  -1.50 29i 1.50 
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   corc1  -2.50  9i 2.50 
endmd 
NPS 2.0E6 
PRDMP 1E7 1E8 0 4 
DBCN 18J 1  $ITS-style energy indexing 
PRINT 
c PRINT -10 -40 -50 -70 -98 -85 -86 -110 -140 -170 -130 -128 
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A.2: Eye device inputs  
 
A.2.1 Eye dose profiles at water 
 
 
 
c       Cell    Cards 
c       Pr      source 
c       Pr-glass4.0g/cm3 
5       1      -4.0    -11 -12  13  imp:p,e=1 
c 
900       3      -1  -5 imp:p,e=4 
950       2      -0.0012  -6  #900 #5 imp:p,e=1 
c       void 
999     0 #5 #900 #950  imp:p,e=0 
c       end     of      cell    cards 
c *********************************************************** 
c                          surface card block 
c                         * surface of water * 
c                             Pr Glass Rod 
11  CX         0.075 
12  PX          0 
13  PX         -0.50 
c 14  PZ         0.5 
c 2   SX         2.5      3.0  
c 3   SX         2.5      3.1 
c 4  PX        -0.2 
5   SX         2.0      2.0          $eye surface 
6   SO         4.0 
c 7   PX        -2.0 
c 8   PX         2.0 
c       end of surface card block 
c ************************************************************** 
MODE    p       e 
c       materialcard 
c       Pr 
c       Si:Al:Pr0.153:0.) 
m1         14000  -0.153   13000  -0.081   59000  -0.445    8000  -0.322 
c        * air * 
c   C : 0.0125%    N : 75.5267     O : 23.1781     Si : 1.2827% 
m2 006000 -0.0125 007014 -75.5267 008016 -23.1781 018000 -1.2827 
c       water 
c       H       :       2O      :              1 
m3          1001       2    8016       1 
SDEF    cell=5 POS=2.5 0 0  ERG=d1 PAR=3   rad=d2  eff=0.0001 AXS=1 0 0 EXT=d3 
c       SDEF    cell=5  ERG=D1  PAR=3   rad=d2 
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SI1  A  0.017 0.172 0.265 0.395 0.574 0.766 0.877 0.946 1.026 1.188  
        1.268 1.343 1.615 1.712 1.884 1.923 2.011 2.064 2.104 2.139 2.160 
SP1  D  586   656   673   669   649   632   613   598   578   527   
        497   464   311   244   121   95.2  43.4  19.8  7.32  1.19  0.0069 
c  SI1 L 0.017 0.172 0.265 0.395 0.574 0.766 0.946 1.188 1.343 1.712 2.011 2.104 
c  SP1 D 586   656   673   669   649   632   598   527   464   244   43.4  7.32 
SI2            0     0.075 
SP2          -21      1 
SI3            0     -0.5  $radial sampling range 
SP3          -21       0   $uniform sampling for line 
c       E0 
c       F8:P          10 
c mesh tally 
tmesh 
c  xz plane 
   rmesh1:e pedep 
   cora1  0  60i  2.0 
   corb1  -1.0 60i 1.0  
   corc1  -0.03 2i 0.03 
endmd 
NPS     2.00E+06 
DBCN    18J     1  $ITS-styindexing 
PRDMP   2E6 1E8      0       4 
PRINT 
c PRINT   -10   -40   -50   -70   -98   -85   -86    -110    -140    -170    -130    -128 
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A.2.2 Dose at Water for 142Pr, 90Y and 188Re 
 
 
 
Eye dose profiles at water 
c       Cell    Cards 
c       Pr      source 
c       Pr-glass4.0g/cm3 
c Praseodymium Microsphere 
c 5       1      -4.0     11 -12  13 -14  5  3 -8  imp:p,e=1 
c Yttrium Microsphere 
c 5        1      -3.29    11 -12  13 -14  5  3 -8  imp:p,e=1 
c Rhenium Microsphere 
5        1      -4.00    11 -12  13 -14  5  3 -8  imp:p,e=1 
c 
900       3      -1  -5 imp:p,e=4 
950       2      -0.0012  -6  7 #900 #5 imp:p,e=1 
c       void 
999     0 #5 #900 #950  imp:p,e=0 
c       end     of      cell    cards 
c       surface card block 
c       surface of water 
11  PY        -0.5 
12  PY         0.5 
13  PZ        -0.5 
14  PZ         0.5 
c 2   SX         2.5      3.0  
c 3   SX         2.5      3.1 
3   PX        -0.2 
5   SX         2.0      2.0 
6   SO         4.0 
7   PX        -2.0 
8   PX         2.0 
c       end of surface card block 
MODE    p       e 
c       materialcard 
c       Pr 
c       Si:Al:Pr0.153:0.) 
c m1         14000  -0.153   13000  -0.081   59000  -0.445    8000  -0.322 
c       Y 
c       Si:Al:Y:O 
c m1         14000  -0.194   13000  -0.106   39000  -0.303    8000  -0.397 
c       Si:Al:Re:0 
m1         14000  -0.194   13000  -0.106   75000  -0.303    8000  -0.397 
c   air 
c   C : 0.0125%    N : 75.5267     O : 23.1781     Si : 1.2827% 
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m2 006000 -0.0125 007014 -75.5267 008016 -23.1781 018000 -1.2827 
c       water 
c       H       :       2O      :              1 
m3          1001       2    8016       1 
SDEF    cell=5 POS=2.5 0 0  ERG=d1 PAR=3   rad=d2  eff=0.0001  
c       SDEF    cell=5  ERG=D1  PAR=3   rad=d2 
C Praseodymium Energy Spectrum 
c SI1  A  0.017 0.172 0.265 0.395 0.574 0.766 0.877 0.946 1.026 1.188  
c         1.268 1.343 1.615 1.712 1.884 1.923 2.011 2.064 2.104 2.139 2.160 
c SP1  D  586   656   673   669   649   632   613   598   578   527   
c         497   464   311   244   121   95.2  43.4  19.8  7.32  1.19  0.0069 
c Yttrium Energy Spectrum 
c SI1  A  0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
c         1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 
c SP1  D  406.1 476.2 528.1 566.1 593.4 612.1 623.7 628.8 627.6 619.9 
c         605.2 582.8 552.3 513.1 465.3 409.2 345.9 277.0 205.3 134.3 69.0 
c Rhenium Energy Spectrum 
SI1  A  0.034 0.146 0.263 0.389 0.535 0.676 0.793 0.885 0.978 1.060 
        1.143 1.235 1.318 1.411 1.488 1.668 1.751 1.804 1.911 1.975 2.048 
SP1  D  492.8 580.1 658.1 717.3 759.5 764.1 745.4 717.3 676.8 628.5 
        575.4 509.9 447.6 371.2 308.8 170.0 113.8 84.2 34.3 17.2 4.7 
c  SI1 L 0.017 0.172 0.265 0.395 0.574 0.766 0.946 1.188 1.343 1.712 2.011 2.104 
c  SP1 D 586   656   673   669   649   632   598   527   464   244   43.4  7.32 
SI2            2.5     2.7 
SP2          -21        
c       E0 
c       F8:P          10 
c mesh tally 
tmesh 
c  xz plane 
   rmesh1:e pedep 
   cora1  0   29i  1.6 
   corb1  -0.8  29i  0.8 
   corc1  -0.8  29i  0.8 
endmd 
NPS     2.00E+06 
DBCN    18J     1  $ITS-styindexing 
PRDMP   2E6 1E8      0       4 
PRINT 
c PRINT   -10   -40   -50   -70   -98   -85   -86    -110    -140    -170    -130    -128 
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A.2.3 Eye dose profiles at water: Experimental Geometry 
 
 
 
c       Cell    Cards 
c       Pr      source 
c       Pr-glass4.0g/cm3 
5       1      -4.0    -11 -12  13  imp:p,e=1 
c 
900       3      -1  14 -15 16 -17 18 -19  imp:p,e=4 
950       2      -0.0012  -6  #900 #5 imp:p,e=1 
c       void 
999     0 #5 #900 #950  imp:p,e=0 
c       end     of      cell    cards 
c ********************************************************* 
c                  surface card block 
c                 * surface of water * 
c                     Pr Glass Rod 
c  
11  CX         0.075 
12  PX         0 
13  PX        -0.5 
14  PX     0            $Water Box 2.5 x 2.5 x 2.5 cm3 
15  PX     2.5 
16  PY    -1.25 
17  PY     1.25 
18  PZ    -1.25 
19  PZ     1.25 
c 14  PZ         0.5 
c 2   SX         2.5      3.0  
c 3   SX         2.5      3.1 
c 4  PX        -0.2 
c 5   SX         2.0      2.0 
6   SO         4.0 
c 7   PX        -2.0 
c 8   PX         2.0 
c       end of surface card block 
c ********************************************************* 
MODE    p       e 
c       materialcard 
c       Pr 
c       Si:Al:Pr0.153:0.) 
m1         14000  -0.153   13000  -0.081   59000  -0.445    8000  -0.322 
c       * air * 
c   C : 0.0125%    N : 75.5267     O : 23.1781     Si : 1.2827% 
m2 006000 -0.0125 007014 -75.5267 008016 -23.1781 018000 -1.2827 
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c       water 
c       H       :       2O      :              1 
m3          1001       2    8016       1 
c         
c        Source Definitions 
c  
SDEF    cell=5 POS=-0.25 0 0  ERG=d1 PAR=3   rad=d2  eff=0.0001 AXS=1 0 0 EXT=d3 
c       SDEF    cell=5  ERG=D1  PAR=3   rad=d2 
c  
c       Praseodymium-142 Beta Spectrum 
c  
SI1  A  0.017 0.172 0.265 0.395 0.574 0.766 0.877 0.946 1.026 1.188  
        1.268 1.343 1.615 1.712 1.884 1.923 2.011 2.064 2.104 2.139 2.160 
SP1  D  586   656   673   669   649   632   613   598   578   527   
        497   464   311   244   121   95.2  43.4  19.8  7.32  1.19  0.0069 
c  
c  
c  SI1 L 0.017 0.172 0.265 0.395 0.574 0.766 0.946 1.188 1.343 1.712 2.011 2.104 
c  SP1 D 586   656   673   669   649 632   598   527   464   244   43.4  7.32 
c  
SI2            0     0.075  $radial sampling range 
SP2          -21       1   $radial sampling probability 
SI3            0     -0.5  $radial sampling range 
SP3          -21       0   $uniform sampling for line 
c       E0 
c       F8:P          10 
c mesh tally 
tmesh 
c  xz plane 
   rmesh1:e pedep 
   cora1    0  30i 1.0 
   corb1  -0.5 30i 0.5  
   corc1  -0.5 30i 0.5 
endmd 
NPS     2.00E+06 
DBCN    18J     1  $ITS-styindexing 
PRDMP   2E6 1E8      0       4 
PRINT 
c PRINT   -10   -40   -50   -70   -98   -85   -86    -110    -140    -170    -130    -128 
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APENIDIX B: SELECTED PUBLISHED ABSTRACTS AND AWARDS 
 
 
 
East Carolina University Research and Creative Achievement Week 2012 (Awarded “For Best 
Graduate Poster Presentation in the Natural Sciences Category“) “Dosimetric Investigation of 
Praseodymium-142 in Eye Plaque Brachytherapy using Monte Carlo Simulation” 
AAPM 54th Annual Meeting, Charlotte, NC, 2012 (Oral Presentation) “Dosimetric investigation 
of Praseodymium-142 microspheres for microsphere brachytherapy of nonresectable hepatic 
tumors” 
ASTRO 54th Annual Meeting, Boston, MA, 2012 (Poster Presentation) “Comparative Study of 
BED for the beta emitters Pr-142 and Y-90 and Their Applications in Microsphere 
Brachytherapy of HCC” 
NC HPS Meeting 2013 (Winner of the 2012/2013 NC HPS College Student Research 
Competition) “Dosimetric characterization of Praseodymium-142 for applications in microsphere 
brachytherapy of Hepatocellular Carcinoma using MCNPX Monte Carlo code” 
East Carolina University Research and Creative Achievement Week 2013 (Awarded “For Best 
Graduate Oral Presentation in the Natural Sciences Category“) “Use of Praseodymium-142 in 
microsphere brachytherapy for treating Hepatocellular Carcinoma 
AAPM 55th Annual Meeting, Indianapolis, IN, 2013 (Abstract Accepted) “Use of Biological 
Effective Dose Volume Histograms to evaluate Hepatocellular Carcinoma coverage due to a 
single blood vessel embolized with Yttrium-90 and Praseodymium-142 glass microspheres” 
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ASTRO 55th Annual Meeting, Atlanta, GA, 2013 (Abstract Accepted) “Dosimetry of Rhenium-
188, Praseodymium-142, and Yttrium-90 using Monte Carlo simulation for application in High 
Dose Rate Eye Plaque Brachytherapy” 
